Drak2 inhibitors and methods for their manufacture and use

Novel Drak2 inhibitors address β-cell apoptosis and immunoregulatory issues by inhibiting Drak2 kinase, providing therapeutic benefits for type 2 diabetes and related conditions.

JP2024544556AActive Publication Date: 2024-12-03BIOPOLAR YOUTANG (GUANGDONG) PHARMACEUTICAL CO LTD
View PDF 18 Cites 0 Cited by

Patent Information

Application Number
JP2024528460
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-12
Filing Date
2022-11-11
Publication Date
2024-12-03
Estimated Expiration
2042-11-11

AI Technical Summary

Technical Problem

Drak2 kinase is implicated in the regulation of apoptosis and immunoregulation, leading to increased β-cell apoptosis and impaired glucose tolerance in inflammatory and hyperlipidemic conditions, making it a target for treating type 2 diabetes and related diseases.

Method used

Development of novel Drak2 inhibitors, represented by specific compounds of formula I or their stereoisomers, pharmaceutically acceptable salts, prodrugs, or solvates, which can be administered in drug compositions to target and inhibit Drak2 kinase activity.

Benefits of technology

The Drak2 inhibitors effectively prevent β-cell apoptosis and restore insulin secretion, offering potential therapeutic benefits for type 2 diabetes and other diseases associated with Drak2 activity, including cancer and autoimmune disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544556000001_ABST
    Figure 2024544556000001_ABST
Patent Text Reader

Abstract

Provided are compounds of formula I or stereoisomers or optical isomers, pharma- ceutically acceptable salts, prodrugs or solvates thereof that are useful as Drak2 inhibitors, as well as methods for making said compounds, pharmaceutical compositions, their use as Drak2 inhibitors, and their use in the manufacture of a medicament for preventing and / or treating diseases associated with Drak2. [Formula 1] JPEG2024544556000170.jpg3972
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention is in the field of medicinal chemistry, and specifically relates to Drak2 inhibitors and their preparation and use. [Background technology]

[0002] Drak2 (Death Associated Related Apoptotic Protein Kinase 2) is a member of the death-associated protein kinase DAPK family, is abundantly expressed in the thymus, spleen and lymph nodes, and is primarily involved in the regulation of apoptosis.

[0003] In the literature, both the gene and protein levels of Drak2 were rapidly increased in islet β cells treated with free fatty acids (FFA) and inflammatory cytokines (IL-1β, IFNγ, TNFα), accompanied by an increase in anti-apoptotic factors such as Bcl-2, Bcl-xL, and Flip. The upregulation of these gene and protein levels both promoted increased apoptosis of islet β cells and reduced insulin secretion. At the same time, Drak2 transgenic mice showed poorer glucose tolerance after obesity was induced with a high-fat diet, demonstrating that Drak2 was unfavorable to the survival of islet β cells under simulated inflammatory and high-fat pathological conditions. Therefore, Drak2 may be a new target to prevent apoptosis of islet β cells, restore their function, and fundamentally treat type 2 diabetes.

[0004] In addition to its role in regulating apoptosis, Drak2 also has immune regulatory functions, negatively regulating T cell activation, and is closely related to T cell survival and differentiation, tumor immunoregulation, and autoimmunity. Therefore, the development of new Drak2 inhibitors is necessary. Summary of the Invention [Problem to be solved by the invention]

[0005] The object of the present invention is to provide new Drak2 inhibitors with potential broad clinical applications. [Means for solving the problem]

[0006] In a first aspect of the present invention there is provided a compound of formula I, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof. [ka] (where: X1 is N or CR m1 Selected from. X2 is N or CR m2 Selected from. X3 is N or CR m3 Selected from. X5 is N or CR' m3 Selected from. L is a bond, -O-, -S, or -NR m4 -, -C(O)- or -C(O)NR m4 -Selected from. Ring A and ring B are each independently selected from a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, and a 5-12 membered heteroaryl group, wherein the C3-C12 cycloalkyl group, the 3-12 membered heterocyclic group, the C6-C10 aryl group, and the 5-12 membered heteroaryl group are optionally substituted with 1-3 R. Each R m are independently H, D, halogen, cyano group, hydroxy group, carboxy group, -S(O) t R m5 , -C(O)R m5 , -C(O)OR m5 , -C(O)NR m6 R m7 , -S(O) t NR m6 R m7 , -C(O)NR m8 S(O) t NR m6 R m7 , -(CH2) qS(O) t R m5 , -(CH2) q C(O)R m5 , -(CH2) q C(O)OR m5 , -(CH2) q C(O)NR m6 R m7 , -(CH2) q (CH2) q S(O) t NR m6 R m7 , -C(O)NR m8 S(O) t NR m6 R m7 , -(CH2) q R m9 , -C1-C6 alkyl group, -C1-C6 alkoxy group, -C1-C6 alkylamine group, C3-C12 cycloalkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group is optionally substituted by 1-3 R. Alternatively, two R on adjacent ring atoms m together with the ring atoms adjacent thereto form a C3-C12 cycloalkyl group or a 3-12 membered heterocyclic group, wherein the C3-C12 cycloalkyl group or the 3-12 membered heterocyclic group is optionally substituted with 1-3 R. R n is H, C1-C15 alkyl group, C2-C15 alkenyl group, C2-C15 alkynyl group, C(O)R p where R pis selected from NH2, a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C2-C15 alkenyl group, a C2-C15 alkynyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C15 alkyl group, C1-C15 alkoxy group, C1-C15 alkylamine group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group is optionally substituted with 1-3 R. R m1 , R m2 , R m3 and R' m3 are each independently selected from H, a cyano group, a halogen, C(O)NH2, a carboxy group, S(O)2NH2, a C(O)OC1-C6 alkyl group, or a S(O)2C1-C6 alkyl group. R m4 is selected from H or a C1-C6 alkyl group. R m5 is selected from a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group is optionally substituted by 1-3 R. R m6 , R m7 , R m8 and R m9 are each independently selected from H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group; or R m6 and R m7together with the N atom adjacent thereto, form a 3-12 membered heterocyclic group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 R. (CH2) q H in is optionally replaced by R. R is selected from H, D, halogen, cyano, hydroxy, carboxy, NH2, oxo (=O), C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamine, C(O)OC1-C6 alkyl, S(O)2C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl or 5-12 membered heteroaryl, wherein The C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 groups selected from the group consisting of halogen, cyano group, hydroxy group, carboxy group, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group and S(O)2C1-C6 alkyl group. t is 0, 1, or 2. q is 1, 2, 3, 4, 5 or 6. n is 1, 2, 3, 4, 5 or 6.

[0007] In another preferred embodiment, the compound, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof, has the structure represented by Formula II: [ka] (wherein X1, X2, X3, X5, ring A, ring B, R m , R p and n are defined as above.)

[0008] In another preferred embodiment, ring A is selected from a phenyl group, a C5-C6 cycloalkyl group, a 5-6 membered heteroaryl group, or a 5-6 membered heteroaryl group, preferably a phenyl group. In another preferred embodiment, Ring B is a 5-6 membered heteroaryl group, preferably a thienyl group or a thiazolyl group.

[0009] In another preferred embodiment, the compound, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof, has the structure represented by Formula III. [ka] (where X4 is N or CR m10 where R m10 is selected from H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, or R m6 and R m7 together with the N atom adjacent thereto, form a 3-12 membered heterocyclic group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 R. R' is selected from H, D, halogen, cyano, hydroxy, carboxy, NH2, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 alkylamine, and is preferably H. R, X1, X2, X3, X5, Ring A, R m , R p and n are defined as above.) In another preferred embodiment, [ka] teeth, [ka] and preferably [ka] It is. In another preferred embodiment, the compound, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof, has the structure represented by formula IV. [ka] (where: R1, R2, R3, R4, and R5 each independently represent H, D, a halogen atom, a cyano group, a hydroxyl group, a carboxyl group, or -S(O). t R m5 , -C(O)R m5 , -C(O)OR m5 , -C(O)NR m6 R m7 , -S(O) t NR m6 R m7 , -C(O)NR m8 S(O) t NR m6 R m7 , -(CH2) q S(O) t R m5 , -(CH2) q C(O)R m5 , -(CH2) q C(O)OR m5 , -(CH2) q C(O)NR m6 R m7 , -(CH2) q (CH2) q S(O) t NR m6 R m7 , -C(O)NR m8 S(O) t NR m6 R m7 , -(CH2) q R m9, -C1-C6 alkyl group, -C1-C6 alkoxy group, -C1-C6 alkylamine group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group is optionally substituted by 1-3 R. Alternatively, R1 and R2, or R2 and R3, or R3 and R4, or R4 and R5 together with the C atom adjacent thereto form a 5-6 membered heterocyclic group, wherein the 5-6 membered heterocyclic group is optionally substituted with 1-3 R. R' is selected from H, D, halogen, cyano, hydroxy, carboxy, NH2, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 alkylamine, and is preferably H. t, q, R, R m5 , R m6 , R m7 , R m8 , R m9 , X1, X2, X3, X5, R p and n are defined as above.)

[0010] In another preferred embodiment, R1 is H. In another preferred embodiment, R4 is H. In another preferred embodiment, R5 is H. In another preferred embodiment, R1 is H, R4 is H and R5 is H. In another preferred embodiment, R2 is a C1-C6 alkoxy group (preferably a methoxy group).

[0011] In another preferred embodiment, R3 is a C1-C6 alkoxy group (preferably a methoxy group), C(O)NR m6 R m7 or S(O)NR m6 R m7 So, here, R m6 and R m7 The definition is as above. In another preferred embodiment, R3 is a C1-C6 alkoxy 3-6 membered heterocyclic group (preferably -O-CH2-3-6 membered heterocyclic group, -O-CH2CH2-3-6 membered heterocyclic group, etc.), and the C1-C6 alkoxy 3-6 membered heterocyclic group may be substituted with 1-4 halogens, C1-C6 alkyl groups.

[0012] In another preferred embodiment, the compound, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof, has the structure represented by Formula A: [ka] (where: R6 is selected from H, D, halogen, cyano, hydroxy, carboxy, NH2, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 alkylamine, and is preferably H. R7 is selected from a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C15 alkyl group, C1-C15 alkoxy group, C1-C15 alkylamine group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group; The aryl group is optionally substituted with 1 to 3 groups selected from the group consisting of D, halogen, cyano, hydroxy, carboxy, NH, oxo (=O), C-C alkyl, C-C alkoxy, C-C alkylamine, C(O)OC-C alkyl, S(O)C-C alkyl, C-C cycloalkyl, 3-12 membered heterocyclic, C-C aryl, or 5-12 membered heteroaryl. The definitions of R1, R2, R3, R4 and R5 are as above.)

[0013] In another preferred embodiment, R2 and R3 together with the adjacent C atoms form a 5-6 membered heterocyclic group, preferably R2 and R3 together with the adjacent C atoms [ka] It is composed of:

[0014] In another preferred embodiment, the compound, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof, has the structure represented by Formula B: [ka] (where: R7 is selected from a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C15 alkyl group, C1-C15 alkoxy group, C1-C15 alkylamine group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group; The aryl group is optionally substituted with 1 to 3 groups selected from the group consisting of D, halogen, cyano, hydroxy, carboxy, NH, oxo (=O), C-C alkyl, C-C alkoxy, C-C alkylamine, C(O)OC-C alkyl, S(O)C-C alkyl, C-C cycloalkyl, 3-12 membered heterocyclic, C-C aryl, or 5-12 membered heteroaryl. R8 and R9 are each independently H, S(O)2NR 11 R 12, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, or R8 and R9 together with the N atom adjacent thereto form a 3-12 membered heterocyclic group (preferably a 5-6 membered heterocyclic group), wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, 5-6 membered heterocyclic group, C6 The -C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C(O)OC1-C6 alkyl group, an S(O)2C1-C6 alkyl group, a C3-C12 cycloalkyl group, a C1-C6 alkyl C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C1-C6 alkyl 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group. R 11 and R 12 are each independently selected from H, a C1-6 alkyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group.

[0015] In another preferred embodiment, [ka] teeth, [ka] Selected from.

[0016] In another preferred embodiment, the compound, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof, has the structure represented by Formula C: [ka] (where: R 10is selected from H, a cyano group, and CONH2. R7 is selected from a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, among which the C1-C15 alkyl group, C1-C15 alkoxy group, C1-C15 alkylamine group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group is preferably selected from the group consisting of C1-C15 alkyl group, C1-C15 alkoxy group, C1-C15 alkylamine group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group. The aryl group is optionally substituted with 1-3 groups selected from the group consisting of D, halogen, cyano, hydroxy, carboxy, NH, oxo (=O), C-C alkyl, C-C alkoxy, C-C alkylamine, C(O)OC-C alkyl, S(O)C-C alkyl, C-C cycloalkyl, 3-12 membered heterocyclic, C-C aryl, or 5-12 membered heteroaryl.

[0017] In another preferred embodiment, X1 is N or CH. In another preferred embodiment, X2 is N or CH. In another preferred embodiment, X3 is N, CC(=O)NH2, or C-CN. In another preferred embodiment, X5 is N or CH.

[0018] In another preferred embodiment, [ka] teeth, [ka] It is. In another preferred embodiment, L is a bond. In another preferred embodiment, L is NH.

[0019] In another preferred embodiment, ring A is a C6-C10 aryl group or a 3-12 membered heterocyclic group, wherein the 3-12 membered heterocyclic group is preferably a 5-7 membered heterocyclic group, more preferably a 6 membered heterocyclic group, and the definition of the substituents on ring A is the same as that of R above. m (the number of substituents is the same as n).

[0020] In another preferred embodiment, ring A is a benzene ring. [ka] The definition of the substituent in ring A (the position of the substituent may be any position where H is present, including H in -NH-) is as above R m (the number of substituents is the same as n).

[0021] In another preferred embodiment, ring B is a 5-12 membered heteroaryl group or a C3-C12 cycloalkyl group, preferably a 5 membered heteroaryl group or a 6 membered cycloalkyl group, and the substituents on ring B are defined as R above.

[0022] In another preferred embodiment, ring B is [ka] The substituents on ring B are defined as R above.

[0023] In another preferred embodiment, R m is a methoxy group, a fluorine group, a chlorine group, a cyano group, a hydroxy group, a carboxy group, a carboxamide group, [ka] It is.

[0024] In another preferred embodiment, R n teeth, [ka] It is.

[0025] In another preferred embodiment, the compound has a structure represented by formula I'. [ka] (where: X is selected from O or CH2. X1 is N or CR m1 Selected from. X2 is N or CR m2 Selected from. X3 is N or CR m3 Selected from. X5 is N or CR' m3 Selected from. L is a bond, -O-, -S, or -NR m4 -, -C(O)- or -C(O)NR m4 -Selected from. Ring A and ring B are each independently selected from a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, and a 5-12 membered heteroaryl group, wherein the C3-C12 cycloalkyl group, the 3-12 membered heterocyclic group, the C6-C10 aryl group, and the 5-12 membered heteroaryl group are optionally substituted with 1-3 R. Each R m are independently H, D, halogen, cyano group, hydroxy group, carboxy group, -S(O) t R m5 , -C(O)R m5 , -C(O)OR m5 , -C(O)NR m6 R m7 , -S(O) t NR m6 R m7 , -C(O)NR m8 S(O) t NR m6 R m7 , -(CH2) q S(O) t R m5 , -(CH2) q C(O)R m5 , -(CH2) q C(O)OR m5 , -(CH2) qC(O)NR m6 R m7 , -(CH2) q (CH2) q S(O) t NR m6 R m7 , -C(O)NR m8 S(O) t NR m6 R m7 , -(CH2) q R m9 , -C1-C6 alkyl group, -C1-C6 alkoxy group, -C1-C6 alkylamine group, C3-C12 cycloalkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group is optionally substituted by 1-3 R. Alternatively, two R on adjacent ring atoms m together with the ring atoms adjacent thereto form a C3-C12 cycloalkyl group or a 3-12 membered heterocyclic group, wherein the C3-C12 cycloalkyl group or the 3-12 membered heterocyclic group is optionally substituted with 1-3 R. R n is H, C1-C15 alkyl group, C2-C15 alkenyl group, C2-C15 alkynyl group, C(O)R p where R p is selected from NH2, a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C2-C15 alkenyl group, a C2-C15 alkynyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C15 alkyl group, C1-C15 alkoxy group, C1-C15 alkylamine group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group is optionally substituted with 1-3 R. R m1 , R m2 , R m3 and R' m3are each independently selected from H, a cyano group, a halogen, C(O)NH2, a carboxy group, S(O)2NH2, a C(O)OC1-C6 alkyl group, or a S(O)2C1-C6 alkyl group. R m4 is selected from H or a C1-C6 alkyl group. R m5 is selected from a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group is optionally substituted by 1-3 R. R m6 , R m7 , R m8 and R m9 are each independently selected from H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group; or R m6 and R m7 together with the N atom adjacent thereto, form a 3-12 membered heterocyclic group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 R. (CH2) q H in is optionally replaced by R. R is selected from H, D, halogen, cyano, hydroxy, carboxy, NH2, oxo (=O), C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamine, C(O)OC1-C6 alkyl, S(O)2C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl or 5-12 membered heteroaryl, wherein The C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 groups selected from the group consisting of halogen, cyano group, hydroxy group, carboxy group, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group and S(O)2C1-C6 alkyl group. t is 0, 1, or 2. q is 1, 2, 3, 4, 5 or 6. n is 1, 2, 3, 4, 5 or 6.

[0026] In another preferred embodiment, [ka] OR p So, here, R pis a C1-C15 alkyl group (preferably a C1-C6 alkyl group), wherein the C1-C15 alkyl group (preferably a C1-C6 alkyl group) is optionally substituted with 1, 2 or 3 R, and R is a C1-C15 alkylamine group, wherein the C1-C15 alkylamine group is optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, cyano group, hydroxy group, carboxy group, C1-C6 alkyl group, C1-C6 haloalkyl group, C6-C10 aryl group substituted with C1-C6 haloalkyl group, C1-C6 haloalkoxy group, C6-C10 aryl group substituted with C1-C6 haloalkoxy group, C(O)C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group and S(O)2C1-C6 alkyl group, preferably [ka] teeth [ka] It is.

[0027] In another preferred embodiment, the compound satisfies one or more of the following conditions: (1) X1 is N or CH; (2) X2 is N or CH; (3) X3 is N, CC(=O)NH2 or C-CN; (4) X5 is N or CH; (5) L is a bond or NH; (6) Ring A is a C6-C10 aryl group or a 3-12 membered heterocyclic group, wherein the 3-12 membered heterocyclic group is preferably a 5-7 membered heterocyclic group, more preferably a 6 membered heterocyclic group, and preferably, Ring A is a benzene ring, [ka] The definition of the substituent in ring A (the position of the substituent may be any position where H is present, including H in -NH-) is as above R m (the number of substituents is the same as n); (7) Ring B is a 5-12 membered heteroaryl group or a C3-C12 cycloalkyl group, preferably a 5 membered heteroaryl group or a 6 membered cycloalkyl group, preferably Ring B is [ka] and the substituents in ring B are defined as R above; (8)R m is a methoxy group, a fluorine group, a chlorine group, a cyano group, a hydroxy group, a carboxy group, a carboxamide group, [ka] is; (9)R n teeth, [ka] H, acetyl group, isobutyryl group, [ka] A cyclopropylcarbonyl group, a cyclobutylcarbonyl group, a cyclopentylcarbonyl group, a cyclohexylcarbonyl group, a phenylcarbonyl group, a cyclopropylmethylenecarbonyl group, a cyclobutylmethylenecarbonyl group, a cyclopentylmethylenecarbonyl group, a cyclohexylmethylenecarbonyl group, or [ka] is; especially, [ka] teeth, [ka] It is.

[0028] In another preferred embodiment, X1, X2, X3, X5, ring A, ring B, R m , R p, n, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R 10 are the corresponding groups for each specific compound in the Examples.

[0029] In another preferred embodiment, R is selected from a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C(O)OC1-C6 alkyl group, an S(O)2C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, the C1-C6 alkoxy group, the C3-C12 cycloalkyl group, the 3-12 membered heterocyclic group, the C6-C10 aryl group, or the 5-12 membered heteroaryl group. The group or 5-12 membered heteroaryl group is optionally substituted with 1-3 groups selected from the group consisting of halogen, cyano, hydroxy, carboxy, C1-C6 alkyl, C6-C10 aryl substituted with C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6-C10 aryl substituted with C1-C6 haloalkoxy, and C(O)C1-C6 alkylC1-C6 alkylamine, C(O)O-C1-C6 alkyl, and S(O)2C1-C6 alkyl.

[0030] In another preferred embodiment, Rn is C(O)R p where R p is selected from a C1-C15 alkyl group (preferably a C1-C6 alkyl group), wherein said C1-C15 alkyl group (preferably a C1-C6 alkyl group) is optionally substituted with 1, 2 or 3 R, and R is selected from a C3-C12 cycloalkyl group, wherein said C3-C12 cycloalkyl group is optionally substituted with 1, 2 or 3 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C6-C10 aryl group substituted with a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C6-C10 aryl group substituted with a C1-C6 haloalkoxy group, and a C(O)C1-C6 alkyl group.

[0031] In another preferred embodiment, Rn is OR p where R p is selected from a C1-C15 alkyl group, wherein the C1-C15 alkyl group is optionally substituted with 1, 2 or 3 R, and R is selected from a C1-C15 alkylamine group, wherein the C1-C15 alkylamine group is optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, cyano group, hydroxy group, carboxy group, C1-C6 alkyl group, C1-C6 haloalkyl group, C6-C10 aryl group substituted with C1-C6 haloalkyl group, C1-C6 haloalkoxy group, C6-C10 aryl group substituted with C1-C6 haloalkoxy group, C(O)C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group and S(O)2C1-C6 alkyl group.

[0032] In another preferred embodiment, ring A is [ka] The substituents in ring A (the positions of the substituents may be any positions where H is present, including H in -NH-) are defined as above for R m (the number of substituents is the same as n).

[0033] In another preferred embodiment, [ka] teeth, [ka] where R m The definition is as above.

[0034] In another preferred embodiment, ring B is [ka] The substituents in ring B are defined as R above.

[0035] In another preferred embodiment, R m teeth, [ka] Selected from.

[0036] In another preferred embodiment, Rn is [ka] Selected from. In another preferred embodiment, n is 0.

[0037] In another preferred embodiment, the compound is selected from the following: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0038] In a second aspect of the invention, there is provided a pharmaceutical composition comprising a compound according to the first aspect or a stereoisomer or optical isomer, or a pharma- ceutically acceptable salt, prodrug or solvate thereof, and a pharma- ceutically acceptable carrier.

[0039] In another preferred embodiment, there is provided a method for preparing a pharmaceutical composition, comprising the step of mixing a pharma- ceutically acceptable carrier with a compound according to the first aspect of the present invention or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof to form a pharmaceutical composition.

[0040] In another preferred embodiment, the compounds of the present invention may be prepared as powders, tablets, granules, capsules, solutions, emulsions, suspensions, and the like.

[0041] In a third aspect of the present invention, there is provided the use of a compound according to the first aspect, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof, or a pharmaceutical composition according to the second aspect, for the manufacture of a medicament for treating or preventing a disease associated with the activity or expression level of Drak2 kinase, or for the manufacture of a medicament for inhibiting the activity of Drak2 kinase.

[0042] Preferably, the disease is cancer, an autoimmune disease or a metabolic disease, Here, the cancer is preferably malignant lymphoma, acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, diffuse large B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, basal cell carcinoma, breast cancer, brain cancer, adrenal cancer, kidney cancer, nephroblastoma, gastric cancer, gastrointestinal stromal tumor, pituitary adenoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon cancer, rectal cancer, small intestine cancer, duodenal cancer, retinoblastoma, choroidal melanoma, ampullary cancer, bladder ... selected from bladder cancer, peritoneal cancer, parathyroid cancer, nasal and paranasal sinus cancer, small cell lung cancer, non-small cell lung cancer (lung adenocarcinoma, lung squamous cell carcinoma), astrocytoma, esophageal cancer, glioma, neuroblastoma, malignant soft tissue tumor, malignant bone tumor, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, penile cancer, oral cancer, lip cancer, pharyngeal cancer, epithelial ovarian cancer, ovarian germ cell cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, vaginal cancer, Paget's disease, tonsil cancer, anal cancer, rhabdomyosarcoma, Kaposi's sarcoma, sarcoma, tongue cancer, laryngeal cancer, pleural cancer, thymic cancer, or a combination thereof; The autoimmune disease is preferably selected from inflammatory colitis, Crohn's disease, Behcet's disease, multiple sclerosis, macular degeneration, arthritis, encephalitis, viral meningitis, or a combination thereof; Said metabolic disease is preferably selected from diabetes, said diabetes being preferably type 1 or type 2 diabetes, more preferably type 2 diabetes.

[0043] Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0044] The present inventors have conducted extensive and in-depth research and have unexpectedly found a new Drak2 inhibitor for the first time, which has a novel structure and good biological activity and safety. Based on this, the present invention has been completed.

[0045] term In the present invention, unless otherwise specified, the terms used have the ordinary meanings known to those skilled in the art. When a substituent is depicted by a conventional chemical formula written from left to right, the substituent includes the chemically equivalent substituent that would result if the structural formula were written from right to left. For example, -CH2O- is equivalent to -OCH2-.

[0046] As used herein, when used with a specific exemplified numerical value, the term "about" means that the value may vary from the exemplified numerical value by up to 1%. For example, as used herein, the designation "about 100" includes 99 and 101 and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0047] As used herein, the terms "containing" or "comprises" may refer to open, semi-closed and closed systems. In other words, the terms also include "consisting essentially of" or "consisting of."

[0048] As used herein, the term "alkyl group" includes straight or branched chain alkyl groups. For example, a C1-C6 alkyl group refers to a straight or branched chain alkyl group having 1-6 carbon atoms, and the alkyl group is preferably a C1-C6 alkyl group. 15 Alkyl groups, more preferably C1-C 10 Alkyl groups are more preferably C1-C6 alkyl groups, more preferably C1-C4, more preferably C1-C3. Alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, and the like. In the present invention, alkyl groups may be optionally substituted or unsubstituted, and substituted alkyl groups include haloalkyl groups, benzyl groups, and the like.

[0049] As used herein, the term "alkenyl group" includes straight or branched chain alkenyl groups, for example, a C2-C6 alkenyl group is a straight or branched chain alkenyl group having 2-6 carbon atoms, such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, and the like.

[0050] As used herein, the term "alkynyl group" includes straight or branched chain alkynyl groups, for example, a C2-C6 alkynyl group is a straight or branched chain alkynyl group having from 2 to 6 carbon atoms, such as ethynyl, propargyl, butynyl, and the like.

[0051] As used herein, the term "cycloalkyl group" refers to a cyclic alkyl group containing a specific number of C atoms, for example, a "C3-C10 cycloalkyl group" refers to a cycloalkyl group having 3-10 (preferably 3, 4, 5, 6, 7 or 8) carbon atoms. It may be monocyclic, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. It may be bicyclic, such as in the form of bridged or spiro rings. In the present invention, cycloalkyl groups are meant to include substituted cycloalkyl groups.

[0052] As used herein, the term "C1-C6 alkoxy group" refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms and having the formula C1-C6 alkyl-O-, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, and the like.

[0053] As used herein, the term "cycloalkyl group" refers to a cyclic alkyl group containing a specific number of C atoms, for example, a "C3-C12 cycloalkyl group" refers to a cycloalkyl group having 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms. It may be monocyclic, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. It may be bicyclic, such as in the form of bridged or spiro rings. The cycloalkyl group may be fused to an aryl, heteroaryl, or heterocyclic ring, where the ring connected to the parent structure is a cycloalkyl group, such as [ka] etc. As used herein, cycloalkyl groups are meant to include substituted cycloalkyl groups.

[0054] As used herein, a "heterocyclyl" refers to a saturated or partially saturated cyclic group having a heteroatom selected from N, S, and O, for example, a "3-12 membered heterocyclic group" refers to a saturated or partially saturated cyclic group having 3-12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) atoms, of which 1-3 (e.g., 1, 2, or 3) atoms are heteroatoms selected from the group consisting of N, S, and O. It may be monocyclic or bicyclic, for example in the form of a bridged ring or spiro ring. The 3-12 membered heterocyclic group is preferably a 3-8 membered heterocyclic group, more preferably a 3-6 membered or 6-8 membered heterocyclic group. Specific examples include oxetane, azetidine, tetrahydro-2H-pyranyl, piperidyl, piperazyl, tetrahydrofuryl, morpholyl, pyrrolidyl, etc. The heterocyclic group may be condensed to a ring of a heteroaryl, aryl, or cycloalkyl group, where the ring connected to the parent structure is a heterocyclic group, e.g. [ka] And so on.

[0055] As used herein, an "aryl group" refers to an aromatic ring group that does not contain a heteroatom in the ring, and a "C6-C10 aryl group" refers to an aromatic ring group having 6-10 carbon atoms that does not contain a heteroatom in the ring, and the aryl group may be fused to a heteroaryl group, a heterocyclic group, or a cycloalkyl ring, where the ring connected to the parent structure is the ring of the aryl group. Examples include a phenyl group (i.e., a 6-membered aromatic ring), a naphthyl group, etc., where the 6-membered aryl group is meant to include a 6-membered aryl-fused 5-6-membered cycloalkyl group and a 6-membered aryl-fused 5-6-membered heterocycloalkyl group. The aryl group may be optionally substituted or unsubstituted.

[0056] As used herein, a "heteroaryl group" refers to a cyclic aromatic group having 1-3 (e.g., 1, 2 or 3) atoms, the heteroatoms being selected from the group consisting of N, S and O, and a "5-10 membered heteroaryl group" refers to a cyclic aromatic group having 5-12 (e.g., 5, 6, 7, 8, 9, 10, 11 or 12) atoms, of which 1-3 (e.g., 1, 2 or 3) atoms are heteroatoms selected from the group consisting of N, S and O. It may be a monocyclic or condensed ring form. Specific examples may be pyridyl, pyridazyl, pyrimidinyl, pyrazinyl, triazyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, etc. Said heteroaryl ring may be fused to an aryl group, a heterocyclic group or a cycloalkyl ring, where the ring connected to the parent structure is a heteroaryl ring.The heteroaryl group may be optionally substituted or unsubstituted.If substituted, the substituents are preferably independently one or more groups selected from alkyl groups, deuterated alkyl groups, haloalkyl groups, alkoxy groups, haloalkoxy groups, alkenyl groups, alkynyl groups, alkylthio groups, alkylamino groups, halogens, amino groups, nitro groups, hydroxy groups, mercapto groups, cyano groups, cycloalkyl groups, heterocyclic groups, aryl groups, heteroaryl groups, cycloalkylthio groups, oxo groups, amido groups, sulfonamide groups, formyl groups, carboxamide groups, carboxy groups and carboxylate groups.

[0057] As used herein, "halogen" or "halogen atom" refers to F, Cl, Br and I. Preferably, the halogen or halogen atom is selected from F, Cl and Br. As used herein, an "amino group" is -NH2. As used herein, a "carboxy group" is --COOH.

[0058] As used herein, the term "amide group" refers to a group having the structure -CONRR', where R and R' may independently represent hydrogen, alkyl, cycloalkyl, aryl, or heterocyclic groups, as defined above. R and R' may be the same or different in the dialkylamine fragment.

[0059] As used herein, the term "sulfonamide group" refers to a group having the structure -SONRR', where R and R' may independently represent hydrogen, alkyl, cycloalkyl, aryl, or heterocyclic groups, as defined above. R and R' may be the same or different in the dialkylamine fragment. In the present invention, the term "formyl group" refers to a group containing --CHO.

[0060] As used herein, the term "carboxamide group" means [ka] The carboxamide group is also meant to include substituted carboxamide groups, and the formula [ka] where R and R' each independently represent a hydrogen, an alkyl group, a cycloalkyl group, a cycloalkenyl group, an aryl group, a heteroaryl group, or a heterocyclic group, as defined above. Each R may be the same or different.

[0061] As used herein, an "alkylamine group" refers to a group having the structure -N(R)(R') or -alkyl-N(R)(R'), where R and R' each independently represent hydrogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, or a heterocyclic group, as defined above. An "C1-C6 alkylamine group" includes, but is not limited to, NHCH3, N(CH3)2, NHCH2CH3, N(CH2CH3)2, N(CH3)(CH2CH3), CH2NHCH3, CH2CH2NHCH3, CH2CH2CH2NHCH3, CH2N(CH3)2, CH2CH2N(CH3)2, CH2CH2CH2N(CH3)2, CH2N(CH3)(CH2CH3), CH2CH2N(CH3)(CH2CH3), and CH2CH2CH2N(CH3)(CH2CH3).

[0062] As used herein, a "sulfoxide group" refers to a group having the formula -S(O)-R, where R independently represents a hydrogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, or a heterocyclic group, as defined above. As used herein, a "sulfone group" refers to a group having the substituent -S(O)-R, where each R is independently a hydrogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, or a heterocyclic group, as defined above.

[0063] As used herein, an "ester group" refers to a group having the structure -C(O)-OR or -RC(O)-O-, where R independently represents a hydrogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, or a heterocyclic group, as defined above. As used herein, "C3-C12 cycloalkyl C1-C6 alkyl group" is -C3-C12 cycloalkyl C1-C6 alkyl or C3-C12 cycloalkyl C1-C6 alkyl-, and "3- to 12-membered heterocyclic group C1-C6 alkyl group" has an analogous meaning.

[0064] As used herein, "optionally" means that the following event or circumstance is possible but not necessarily occurring, and that the description includes instances where the event or circumstance occurs as well as instances where the event or circumstance does not occur.

[0065] In the present invention, the term "substituted" refers to the replacement of one or more hydrogen atoms in a particular group with a particular substituent. The particular substituents are the corresponding substituents described above or in each example. Unless otherwise stated, a substituted group may have one substituent selected from a particular group at any substitutable position of the group, and the substituents may be the same or different at each position. As will be appreciated by those skilled in the art, the combinations of substituents contemplated by the present invention are stable or chemically feasible combinations.

[0066] Unless specifically described as "substituted or unsubstituted", any of the groups described in the present invention may be substituted with a substituent selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxy, amino, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, 3-10 membered heterocycloalkyl, C3-C10 cycloalkyl, 5-12 membered heteroaryl, and C6-C12 aryl. In the present invention, the term "plurality" refers independently to 2, 3, 4, 5.

[0067] Unless otherwise specified, the structural formulae depicted in the present invention are meant to include all isomeric forms (e.g., enantiomeric, non-enantiomeric and geometric (or conformational) isomers), such as R, S configurations having asymmetric centers, (Z) and (E) isomers at double bonds, etc. Thus, any single stereoisomer of the compounds of the present invention or mixtures of enantiomeric, non-enantiomeric or geometric (or conformational) isomers thereof are within the scope of the present invention.

[0068] As used herein, the term "tautomer" means that structural isomers with different energies can be converted into each other across a low energy barrier. For example, proton tautomers (i.e., prototropes) include those that undergo tautomerization via proton transfer, such as 1H-indazole and 2H-indazole. Valence tautomers include those that undergo tautomerization via rearrangement of some bond electrons. As used herein, the term "solvate" refers to a complex formed by coordination of a compound of the present invention with solvent molecules in a specific ratio.

[0069] active ingredient As used herein, "a compound of the invention" refers to a compound of Formula I, and also includes stereoisomers, pharma- ceutically acceptable salts, prodrugs, or solvates of the compounds of Formula I.

[0070] The compounds of the present invention contain one or more chiral carbon atoms, which give rise to enantiomeric, non-enantiomeric and other stereoisomeric forms. Each chiral carbon atom is defined as (R)- or (S)- based on stereochemistry. The present invention includes all possible isomers, as well as their racemic and optically pure forms. The preparation of the compounds of the present invention may involve the selection of racemic, non-enantiomeric or enantiomeric forms as starting materials or intermediates. Optically active isomers may be prepared with chiral synthesis elements or chiral reagents, or resolved by conventional techniques, such as crystallization or chiral chromatography.

[0071] Conventional techniques for preparing / separating single optical isomers (i.e., enantiomers and non-enantiomers) include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative), e.g., by chiral high performance liquid chromatography, see, e.g., Gerald Gubitz and Martin G. Schmid (Eds.), Chiral Separations, Methods and Protocols, Methods in Molecular Biology, Vol. 243, 2004;AM Stalcup, Chiral Separations, Annu. Rev. Anal. Chem. 3:341-63, 2010;Fumiss et al. (eds.), VOGEL'S ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY 5.sup.TH ED., Longman Scientific and Technical Ltd., Essex, 1991, 809-816; Heller, Acc. Chem. Res. See 1990, 23, 128.

[0072] The present invention also includes isotopically labeled compounds (i.e., isotopic derivatives), equivalent to the parent compounds disclosed herein. In practice, one or more atoms will often be replaced by atoms of different atomic mass or mass number. Examples of isotopes in the isotopic derivatives of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, e.g., 2 H, 3 H, 13 C. 11 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F and 36 All isotopic derivatives of the compounds of the present invention are included within the scope of the present invention. 3 H-labeled compounds and14 C-labeled compounds are useful in drug and substrate tissue distribution studies. 3 H) and carbon-14 (i.e. 14 C) labeled compounds are relatively easy to prepare and detect, and are best with isotopes. Also, heavy isotope substitutions, e.g., deuterium, i.e., 2 H has an advantage in some therapies due to its superior metabolic stability, and may be considered preferred in some cases, for example due to increased half-life or reduced dosage in the body. Isotopically labeled compounds can be prepared by the methods disclosed in the examples by using readily available isotopically labeled reagents in place of nonisotopic reagents in a conventional manner.

[0073] As used herein, the term "pharmaceutically acceptable salts" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0074] A "pharmaceutically acceptable acid addition salt" is a salt formed with an inorganic or organic acid that retains the biological effectiveness of the free base without other adverse effects. Inorganic acid salts include, but are not limited to, hydrochloride, hydrobromide, sulfate, nitrate, phosphate, and the like. Organic acid salts include, but are not limited to, formate, acetate, 2,2-dichloroacetate, trifluoroacetate, propionate, caproate, caprylate, caprate, undecylenate, glycolate, gluconate, lactate, sebacate, adipate, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate, cinnamate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, alginate, ascorbate, salicylate, 4-aminosalicylate, naphthalenedisulfonate, etc. These salts can be prepared by methods known in the art.

[0075] A "pharmacologically acceptable base addition salt" is a salt formed with an inorganic or organic base that retains the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, etc. Preferred inorganic salts are the ammonium, sodium, potassium, calcium and magnesium salts. Salts derived from inorganic bases include, but are not limited to, salts of primary amines, secondary amines and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-methylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Suitable organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.

[0076] When designing the synthesis of a particular enantiomer of one of the compounds of the invention, it can be prepared by asymmetric synthesis or derivatized with a chiral auxiliary, the resulting non-enantiomer separated, and the chiral auxiliary removed to give a single enantiomer.Alternatively, when the molecule contains a basic functionality, e.g., an amino acid, or an acidic functionality, e.g., a carboxy group, the non-enantiomer can be formed with an appropriate optically active acid or base, and the single enantiomer can be obtained after resolution by conventional means such as fractional crystallization or chromatography.

[0077] As described herein, the compounds of the present invention can be substituted with any number of substituents or functional groups to expand their coverage. In general, the term "substituted" refers to the replacement of hydrogen radicals with a substituent of a given structure. When multiple positions in a particular structure are substituted with multiple specific substituents, each position of the substituents can be the same or different. As used herein, the term "substituted" includes all permissible substitutions of organic compounds. In a broad sense, permissible substituents include acyclic, cyclic, branched, unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compounds. In this specification, for example, a heteroatom nitrogen can be supplemented with a hydrogen substituent or any of the permissible organic compounds described above to compensate for its valence state. In addition, the present invention does not intend to limit the organic compounds that are permissible for substitution in any way. In the present invention, it is advantageous in the treatment of diseases for the combination of substituents and variables to exist in the form of a stable compound. As used herein for the above purposes, the term "stable" means that a stable compound has sufficient integrity to maintain the structure of the compound to be detectable over a sufficiently long period of time, and preferably remains effective over a sufficiently long period of time.

[0078] Metabolites of the compounds of formula I and their pharma- ceutically acceptable salts, as well as prodrugs that are converted in the body to the compounds of formula I and their pharma- ceutically acceptable salts, are also included in the scope of protection of the present invention.

[0079] Methods for producing compounds In the following schemes, methods for preparing compounds of formula I are described. In some cases, the order of steps of the reaction schemes carried out may be changed to facilitate the reaction or avoid unwanted by-products. In addition, the compounds of the present invention may be conveniently prepared by any combination of various synthetic methods described herein or known in the art, and such combinations are readily accessible to those skilled in the art.

[0080] In general, during the production, each reaction is usually carried out in an inert solvent at room temperature to reflux temperature (for example, 0° C. to 150° C., preferably 10° C. to 100° C.) The reaction time is usually 0.1 to 60 hours, preferably 0.5 to 48 hours.

[0081] Preferably, the compound of the present invention can be produced by the following method. Method 1 Method A: [ka] S1) reacting compound (A-1) with the corresponding borate ester or borate compound (A-1a) (including but not limited to bis(pinacolato)diboron) under suitable basic conditions (including but not limited to potassium acetate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 80° C.), and catalysis of suitable coupling catalyst (including but not limited to Pd(dppf)2) to obtain compound (A-2); S2) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 80° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (A-2) is reacted with a corresponding aryl halide compound (A-2a) (including but not limited to 2,6-dibromopyrazine) to obtain compound (A-3); S3) reacting compound (A-3) with the corresponding boronic acid or boronic acid ester compound (A-3a) under suitable basic conditions (including but not limited to potassium carbonate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 60° C.), and catalysis of suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium) to obtain compound (A-4); S4) reacting compound (A-4) with the corresponding nitrogen-containing compound (A-4a) under suitable basic conditions (including but not limited to cesium carbonate), suitable solvent (including but not limited to toluene), suitable temperature (including but not limited to 110° C.), suitable ligand (including but not limited to BINAP), and catalysis of suitable coupling catalyst (including but not limited to Pd2(dba)3) to obtain compound (A-5-1); S5) Select an appropriate solvent (including but not limited to tetrahydrofuran, etc.) and an appropriate acid (including but not limited to 1M hydrochloric acid) to deprotect compound (A-5-1) to obtain compound (A-5); S6) Select a suitable solvent (including but not limited to dichloromethane) and a suitable base (including but not limited to triethylamine) to react compound (A-5) with the corresponding acyl chloride (A-5a) to obtain compound (A).

[0082] Method B: [ka] S1) reacting compound (A-1) with the corresponding borate ester or borate compound (A-1a) (including but not limited to bis(pinacolato)diboron) under suitable basic conditions (including but not limited to potassium acetate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 80° C.), and catalysis of suitable coupling catalyst (including but not limited to Pd(dppf)2) to obtain compound (A-2); S2) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 80° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (A-2) is reacted with a corresponding aryl halide compound (A-2a) (including but not limited to 2,6-dibromopiperazine) to obtain compound (A-3); S3) reacting compound (A-3) with the corresponding boronic acid or boronic acid ester compound (A-3a) under suitable basic conditions (including but not limited to potassium carbonate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 60° C.), and catalysis of suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium) to obtain compound (A-4); S4) Under suitable basic conditions (including but not limited to potassium carbonate), suitable solvents (including but not limited to DMSO), suitable temperatures (including but not limited to 110° C.), suitable ligands (including but not limited to L-proline), and catalysis of suitable coupling catalysts (including but not limited to cuprous iodide), compound (A-4) is reacted with the corresponding nitrogen-containing compound, aqueous ammonia, under sealed tube conditions to obtain compound (A-5); S5) Select a suitable solvent (including but not limited to dichloromethane) and a suitable base (including but not limited to triethylamine) to react compound (A-5) with the corresponding acyl chloride (A-5a) to obtain compound (A).

[0083] Method 2 [ka] S1) reacting compound (B-1) with the corresponding borate ester or borate compound (B-1a) (including but not limited to bis(pinacolato)diboron) under suitable basic conditions (including but not limited to potassium acetate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 80° C.), and catalysis of suitable coupling catalyst (including but not limited to Pd(dppf)2) to obtain compound (B-2); S2) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 80° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (B-2) is reacted with the corresponding aryl halide compound (B-2a) to obtain compound (B-3); S3) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 60° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (B-3) is reacted with a corresponding boronic acid or boric acid ester compound (B-3a) to obtain compound (B-4); S4) Under suitable basic conditions (including but not limited to potassium carbonate), suitable solvents (including but not limited to DMSO), suitable temperatures (including but not limited to 110° C.), suitable ligands (including but not limited to L-proline), and catalysis of suitable coupling catalysts (including but not limited to cuprous iodide), compound (B-4) is reacted with the corresponding nitrogen-containing compound, aqueous ammonia, under sealed tube conditions to obtain compound (B-5); S5) Select a suitable solvent (including but not limited to dichloromethane, etc.), select a suitable base (including but not limited to triethylamine), and react compound (B-5) with the corresponding acyl chloride (B-5a) to obtain compound (B-6); S6) Select an appropriate solvent (including, but not limited to, a mixed solvent of tetrahydrofuran and water) and an appropriate base (including, but not limited to, lithium hydroxide) to hydrolyze compound (B-6) to obtain carboxy compound (B-7); S7) Select a suitable solvent (including but not limited to DMF) and a suitable condensation reagent (including but not limited to EDCI+HOBT) under suitable basic (including but not limited to DIEA) conditions to react compound (B-7) with the corresponding amine (B-7a) to obtain compound (B-8).

[0084] Method 3 [ka] S1) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 80° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (C-1) is reacted with the corresponding aryl halide compound (C-1a) to obtain compound (C-2); S2) reacting compound (C-2) with the corresponding boronic acid or boronic acid ester compound (C-2a) under suitable basic conditions (including but not limited to potassium carbonate), suitable solvent (including but not limited to dioxane and water mixture), suitable temperature (including but not limited to 60° C.), and catalysis of suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium) to obtain compound (C-3); S3) reacting compound (C-3) with the corresponding nitrogen-containing compound (C-3a) under suitable basic conditions (including but not limited to cesium carbonate), suitable solvent (including but not limited to toluene), suitable temperature (including but not limited to 110° C.), suitable ligand (including but not limited to BINAP), and catalysis of suitable coupling catalyst (including but not limited to Pd2(dba)3) to obtain compound (C-4); S4) Select an appropriate solvent (including but not limited to tetrahydrofuran, etc.) and an appropriate acid (including but not limited to 1M hydrochloric acid) to deprotect compound (C-4) to obtain compound (C-5); S5) Select a suitable solvent (including but not limited to dichloromethane) and a suitable base (including but not limited to triethylamine) to react compound (C-5) with the corresponding acyl chloride (C-5a) to obtain compound (C-6); S6) A suitable solvent (including but not limited to t-butanol) and a suitable base (including but not limited to sodium t-butoxide) are selected to hydrolyze compound (C-6) to obtain amide compound (C-7).

[0085] Drug Compositions and Methods of Application Since the compounds of the present invention have excellent inhibitory activity against Drak2 kinase, pharmaceutical compositions containing the compounds of the present invention as their main active ingredients are useful for preventing and / or treating (stabilizing, alleviating or curing) diseases associated with Drak2 kinase.

[0086] The pharmaceutical composition of the present invention comprises the compound of the present invention in a safe and effective amount and a pharma- ceutically acceptable excipient or carrier. Here, the term "safe and effective amount" refers to the amount of the compound that is sufficient to significantly improve the disease condition and does not cause severe side effects. Usually, the pharmaceutical composition contains the compound of the present invention in an amount of 1-2000 mg / formulation, preferably 10-200 mg / formulation. Preferably, the "formulation" is a capsule or tablet.

[0087] "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel substances that must be applicable to humans and have sufficient purity and sufficiently low toxicity. "Compatibility" refers to the ability of each component in the drug composition to be blended with and among the compounds of the present invention without significantly reducing the effect of the compound. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyhydric alcohols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., tallow, glyceryl ... R ), humectants (e.g., sodium dodecyl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, and pyrogen-free distilled water.

[0088] The mode of administration of the compound or pharmaceutical composition of the present invention is not particularly limited, but typical modes of administration include, but are not limited to, oral administration, parenteral (intravenous, intramuscular, or subcutaneous) administration.

[0089] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the compound of the present invention is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or may contain (a) a filler or compatibilizer, such as starch, lactose, sucrose, glucose, mannitol or silicic acid, (b) a binder, such as hydromethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose or gum arabic, (c) a humectant, such as glycerin, (d) a disintegrant, such as agar, carbonate, or the like. It is mixed with ingredients such as calcium, potato starch, tapioca starch, alginic acid, some complex silicates and sodium carbonate, (e) solution retarders such as paraffin, (f) absorption promoters such as ammonium compounds, (g) wetting agents such as cetanol and glycerin monostearate, (h) adsorbents such as kaolin, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage form may contain a buffering agent.

[0090] Solid dosage forms, such as tablets, pills, capsules, pills, and granules, can be prepared with coatings or shells, such as enteric coatings and other materials known in the art. An opacifying agent may be included, and in such pharmaceutical compositions, the release of the compound of the present invention may be delayed in a certain part of the digestive tract. Examples of embedding components that can be used include polymeric materials and wax-based materials. If necessary, the compound of the present invention may be formed into a microcapsule with one or more of the above-mentioned excipients.

[0091] Liquid dosage forms for oral administration include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the compounds of the present invention, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, compatibilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn oil, olive oil, castor oil, or sesame oil, or mixtures of these substances.

[0092] Besides these inert diluents, the pharmaceutical composition may also include adjuvants, such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, and perfuming agents. In addition to the compound of the invention, suspensions may contain suspending agents such as ethoxylated isooctadecanol, polyoxyethylene sorbitol or sorbitan esters, microcrystalline cellulose, methoxyaluminium or agar-agar, or mixtures of these substances.

[0093] Pharmaceutical compositions for parenteral injection include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous or non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols, and suitable mixtures thereof. The compounds of the present invention may be administered alone or in combination with other pharma- ceutically acceptable compounds (eg, EGFR inhibitors).

[0094] When administered in combination, the pharmaceutical composition further comprises one or more (two, three, four or more) other pharma- ceutically acceptable compounds (e.g., Drak2 inhibitors), which one or more (two, three, four or more) of the other pharma- ceutically acceptable compounds (e.g., Drak2 inhibitors) can be used simultaneously, separately or sequentially with the compounds of the present invention for the prevention and / or treatment of diseases associated with the activity or expression level of Drak2 kinase.

[0095] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered to a mammal (such as a human) in need of treatment, and the dosage is a pharmacologically effective dosage, for a human weighing 60 kg, the daily dosage is usually 1-2000 mg, preferably 20-500 mg. Of course, the specific dosage should further consider factors such as the mode of administration and the health condition of the patient, all of which are within the skill of a skilled physician.

[0096] The main advantages of the present invention are: 1. The compound of the present invention has a novel structure and has excellent Drak2 kinase inhibitory activity. 2. The compounds of the present invention have good pharmacokinetic and pharmacodynamic properties.

[0097] Specific embodiments The present invention will be further described below with reference to specific examples. It is understood that these examples are only used to explain the present invention and do not limit the scope of the present invention. In the following examples, experimental methods for which no specific conditions are described were usually carried out under normal conditions or conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by weight.

[0098] Working Example In this specification, all temperatures are in degrees Celsius unless otherwise stated. In this specification, all percentages regarding yields are mass percentages. In this specification, all parts are parts by volume and all percentages are percentages by volume unless otherwise stated.

[0099] Herein, PTLC or TLC (thin layer chromatography) preparations were performed on 20×20 cm plates (silica gel 500 μm thick), and a Biotage flash chromatography system was used for silica gel chromatography.

[0100] In this specification, 1H NMR (hydrogen spectra) was performed on a Bruker AscendTM400 spectrometer at 400 MHz, 298°K, and the chemical shifts (in ppm) of residual protons were referenced to the deuterated reagents: δ for CDCl3 is 7.26 ppm, δ for CD3OD is 3.31 ppm, and δ for DMSO-d6 is 2.50 ppm.

[0101] In this specification, the LCMS (liquid chromatography-mass spectrometry) measurements were performed using an Agilent Technologies 1200 series or 6120 quadrupole chromatograph, the mobile phase for liquid chromatography was acetonitrile (A) and water (B) with 0.01% formic acid, and the eluent gradient was 6.0 min 5-95% A, 5.0 min 60-95% A, 5.0 min 80-100% A, and 10 min 85-100% A, using an SBC1850 mm × 4.6 mm × 2.7 μm capillary column, and mass spectrometry (MS) was measured by electrospray ionization (ESI).

[0102] In this specification, the analysis conditions for high performance liquid chromatography (HPLC)-mass spectrometry (MS) are as follows. LC1 column: SB-C18 50 mm × 4.6 mm × 2.7 μm; Temperature: 50℃; Eluent: 5:95 to 95:5 acetonitrile / water (above ratios by volume) + 0.01% formic acid, 6 min; Flow rate: 1.5 mL / min, injection 5 μL; Detection: PDA detector, 200-600 nm; MS: mass range 150-750 amu; cation electrospray ionization. LC2 column: SB-C18 50 mm × 4.6 mm × 2.7 μm; Temperature: 50℃; Eluent: 5:95 to 95:5 acetonitrile / water (above ratios by volume) + 0.05% TFA (trifluoroacetic acid) gradient over 3.00 min; Flow rate: 1.5 mL / min, injection 5 μL; Detection: PDA detector, 200-600 nm; MS: mass range 150-750 amu; cation electrospray ionization. LC3 column: SB-C18 50 mm × 4.6 mm × 2.7 μm; Temperature: 50℃; Eluent: 10:90 to 98:2 acetonitrile / water (above ratios by volume) + 0.05% TFA gradient over 3.75 min; Flow rate: 1.0 mL / min, injection 10 μL; Detection: PDA detector, 200-600 nm; MS: mass range 150-750 amu; cation electrospray ionization.

[0103] In this specification, the meanings of the various abbreviations are as follows: AcOH = acetic acid; Alk = alkyl group; AR = aryl group; Boc = t-butoxycarbonyl group; CH2Cl2 = dichloromethane; DBU = 1,8-diazabicyclo[5.4.0]-7-undecene; DCM = dichloromethane; DEAD = diethyl azodicarboxylate; DMF = N,N-dimethylformamide; DMSO = dimethylsulfoxide; EA = ethyl acetate; Et = ethyl group; EtOAc = ethyl acetate; EtOH = ethanol; HOAc = acetic acid; LiOH = lithium hydroxide; Me = methyl group; MeCN = acetonitrile; MeOH = methanol; MgSO4 = magnesium sulfate; NaCl = sodium chloride; NaOH = sodium hydroxide; Na2SO4 = sodium sulfate; PE = petroleum ether; Ph = phenyl group; PG = protecting group; TFA = trifluoroacetic acid; THF = tetrahydrofuran; Ts = p-toluenesulfonyl group; rt = room temperature; h = hours; min = minutes; bs = broad singlet; s = singlet; d = broad singlet;dd = broad singlet;t = broad singlet;m = broad singlet.

[0104] Common Methods Method 1 Method A: [ka] S1) reacting compound (A-1) with the corresponding borate ester or borate compound (A-1a) (including but not limited to bis(pinacolato)diboron) under suitable basic conditions (including but not limited to potassium acetate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 80° C.), and catalysis of suitable coupling catalyst (including but not limited to Pd(dppf)2) to obtain compound (A-2); S2) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 80° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (A-2) is reacted with a corresponding aryl halide compound (A-2a) (including but not limited to 2,6-dibromopyrazine) to obtain compound (A-3); S3) reacting compound (A-3) with the corresponding boronic acid or boronic acid ester compound (A-3a) under suitable basic conditions (including but not limited to potassium carbonate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 60° C.), and catalysis of suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium) to obtain compound (A-4); S4) reacting compound (A-4) with the corresponding nitrogen-containing compound (A-4a) under suitable basic conditions (including but not limited to cesium carbonate), suitable solvent (including but not limited to toluene), suitable temperature (including but not limited to 110° C.), suitable ligand (including but not limited to BINAP), and catalysis of suitable coupling catalyst (including but not limited to Pd2(dba)3) to obtain compound (A-5-1); S5) Select an appropriate solvent (including but not limited to tetrahydrofuran, etc.) and an appropriate acid (including but not limited to 1M hydrochloric acid) to deprotect compound (A-5-1) to obtain compound (A-5); S6) Select a suitable solvent (including but not limited to dichloromethane) and a suitable base (including but not limited to triethylamine) to react compound (A-5) with the corresponding acyl chloride (A-5a) to obtain compound (A).

[0105] Method B: [ka] S1) reacting compound (A-1) with the corresponding borate ester or borate compound (A-1a) (including but not limited to bis(pinacolato)diboron) under suitable basic conditions (including but not limited to potassium acetate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 80° C.), and catalysis of suitable coupling catalyst (including but not limited to Pd(dppf)2) to obtain compound (A-2); S2) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 80° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (A-2) is reacted with a corresponding aryl halide compound (A-2a) (including but not limited to 2,6-dibromopyrazine) to obtain compound (A-3); S3) reacting compound (A-3) with the corresponding boronic acid or boronic acid ester compound (A-3a) under suitable basic conditions (including but not limited to potassium carbonate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 60° C.), and catalysis of suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium) to obtain compound (A-4); S4) Under suitable basic conditions (including but not limited to potassium carbonate), suitable solvents (including but not limited to DMSO), suitable temperatures (including but not limited to 110° C.), suitable ligands (including but not limited to L-proline), and catalysis of suitable coupling catalysts (including but not limited to cuprous iodide), compound (A-4) is reacted with the corresponding nitrogen-containing compound, aqueous ammonia, under sealed tube conditions to obtain compound (A-5); S5) Select a suitable solvent (including but not limited to dichloromethane) and a suitable base (including but not limited to triethylamine) to react compound (A-5) with the corresponding acyl chloride (A-5a) to obtain compound (A).

[0106] Method 2 [ka] S1) reacting compound (B-1) with the corresponding borate ester or borate compound (B-1a) (including but not limited to bis(pinacolato)diboron) under suitable basic conditions (including but not limited to potassium acetate), suitable solvent (including but not limited to dioxane), suitable temperature (including but not limited to 80° C.), and catalysis of suitable coupling catalyst (including but not limited to Pd(dppf)2) to obtain compound (B-2); S2) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 80° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (B-2) is reacted with the corresponding aryl halide compound (B-2a) to obtain compound (B-3); S3) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 60° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (B-3) is reacted with a corresponding boronic acid or boric acid ester compound (B-3a) to obtain compound (B-4); S4) Under suitable basic conditions (including but not limited to potassium carbonate), suitable solvents (including but not limited to DMSO), suitable temperatures (including but not limited to 110° C.), suitable ligands (including but not limited to L-proline), and catalysis of suitable coupling catalysts (including but not limited to cuprous iodide), compound (B-4) is reacted with the corresponding nitrogen-containing compound, aqueous ammonia, under sealed tube conditions to obtain compound (B-5); S5) Select a suitable solvent (including but not limited to dichloromethane, etc.), select a suitable base (including but not limited to triethylamine), and react compound (B-5) with the corresponding acyl chloride (B-5a) to obtain compound (B-6); S6) Select an appropriate solvent (including, but not limited to, a mixed solvent of tetrahydrofuran and water) and an appropriate base (including, but not limited to, lithium hydroxide) to hydrolyze compound (B-6) to obtain carboxy compound (B-7); S7) Select a suitable solvent (including but not limited to DMF) and a suitable condensation reagent (including but not limited to EDCI+HOBT) under suitable basic (including but not limited to DIEA) conditions to react compound (B-7) with the corresponding amine (B-7a) to obtain compound (B-8).

[0107] Method 3 [ka] S1) Under suitable basic conditions (including but not limited to potassium carbonate), selecting a suitable solvent (including but not limited to a mixture of dioxane and water), at a suitable temperature (including but not limited to 80° C.), and catalyzed by a suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium), compound (C-1) is reacted with the corresponding aryl halide compound (C-1a) to obtain compound (C-2); S2) reacting compound (C-2) with the corresponding boronic acid or boronic acid ester compound (C-2a) under suitable basic conditions (including but not limited to potassium carbonate), suitable solvent (including but not limited to dioxane and water mixture), suitable temperature (including but not limited to 60° C.), and catalysis of suitable coupling catalyst (including but not limited to tetrakis(triphenylphosphine)palladium) to obtain compound (C-3); S3) reacting compound (C-3) with the corresponding nitrogen-containing compound (C-3a) under suitable basic conditions (including but not limited to cesium carbonate), suitable solvent (including but not limited to toluene), suitable temperature (including but not limited to 110° C.), suitable ligand (including but not limited to BINAP), and catalysis of suitable coupling catalyst (including but not limited to Pd2(dba)3) to obtain compound (C-4); S4) Select an appropriate solvent (including but not limited to tetrahydrofuran, etc.) and an appropriate acid (including but not limited to 1M hydrochloric acid) to deprotect compound (C-4) to obtain compound (C-5); S5) Select a suitable solvent (including but not limited to dichloromethane) and a suitable base (including but not limited to triethylamine) to react compound (C-5) with the corresponding acyl chloride (C-5a) to obtain compound (C-6); S6) A suitable solvent (including but not limited to t-butanol) and a suitable base (including but not limited to sodium t-butoxide) are selected to hydrolyze compound (C-6) to obtain amide compound (C-7).

[0108] Example 1 Preparation of N-(5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-yl)pentanamide (A1) (Method A) [ka]

[0109] First step: 3,4-dimethoxyphenylboronic acid pinacol ester (A1-1) 3,4-Dimethoxybromobenzene (910 mg, 4.20 mmol), potassium acetate (1.03 g, 10.50 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (154 mg, 0.21 mmol), bis(pinacolato)diboron (1.28 g, 5.00 mmol) and 1,4-dioxane (40 mL) were added to a reaction bottle in this order, and the reaction was carried out at 80°C for 5 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction solution was filtered, the cake was washed with ethyl acetate, and the reaction solution and the washings were combined and spun to obtain 3,4-dimethoxyphenylboronic acid pinacol ester (A1-1, crude product, 4.20 mmol), which was used in the next step reaction without any purification.

[0110] Second step: 2-bromo-6-(3,4-dimethoxyphenyl)pyrazine (A1-2) 2,6-Dibromopyrazine (1.0 g, 4.2 mmol), 3,4-dimethoxyphenylboronic acid pinacol ester (A1-1, crude product, 4.20 mmol), potassium carbonate (1.38 g, 10.00 mmol), tetrakis(triphenylphosphine)palladium (243 mg, 0.21 mmol), 1,4-dioxane (40 mL) and water (10 mL) were added to a reaction bottle in this order, and the reaction was carried out at 80° C. for 5 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. Most of the 1,4-dioxane was removed by rotary evaporation, and redissolved in ethyl acetate (50 mL). The organic phase was washed with water, saturated brine, dried over anhydrous sodium sulfate, rotary dried and purified by column chromatography to obtain 2-bromo-6-(3,4-dimethoxyphenyl)pyrazine (A1-2, 900 mg, 72.6%). 1HNMR(400 MHz, CDCl3) δ 8.92 (s, 1H), 8.55 (s, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.60 (dd, J = 8.4, 2.1 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 4.02 (s, 3H), 3.98 (s, 3H).

[0111] Third step: 2-(4-bromothiophen-2-yl)-6-(3,4-dimethoxyphenyl)pyrazine (A1-3) 2-Bromo-6-(3,4-dimethoxyphenyl)pyrazine (A1-2, 488 mg, 1.65 mmol), (4-bromothiophen-2-yl)boronic acid (377 mg, 1.82 mmol), tetrakis(triphenylphosphine)palladium (38 mg, 0.033 mmol), potassium carbonate (524 mg, 3.79 mmol), 1,4-dioxane (16 mL) and water (4 mL) were added in a reaction bottle in that order, and the reaction was carried out at 80° C. for 4 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction mixture was rotary evaporated to remove most of the 1,4-dioxane, and then dichloromethane (30 mL) and water (10 mL) were added and the layers were separated. The aqueous phase was extracted with dichloromethane (20 mL x 2), and the organic phases were combined. The organic phase was washed with saturated saline (20 mL x 1), dried over anhydrous sodium sulfate, rotary dried, and purified by column chromatography to obtain 2-(4-bromothiophen-2-yl)-6-(3,4-dimethoxyphenyl)pyrazine (A1-3, 463 mg, 74.4%). 1 H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.78 (s, 1H), 7.74 (d, J = 1.9 Hz, 1H), 7.67 (dd, J = 8.4, 2.0 Hz, 1H), 7.64 (d, J = 1.2 Hz, 1H), 7.40 (d, J = 1.1 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 4.04 (s, 3H), 3.99 (s, 3H).

[0112] Fourth step: N-(5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-yl)-1,1-diphenylmethanimine (A1-4) 2-(4-bromothiophen-2-yl)-6-(3,4-dimethoxyphenyl)pyrazine (A1-3, 106 mg, 0.28 mmol), benzophenone imine (76.4 mg, 0.42 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (17.4 mg, 0.028 mmol), tris(dibenzylideneacetone)dipalladium (12.8 mg, 0.014 mmol), cesium carbonate (136.8 mg, 0.42 mmol) and toluene (10 mL) were added to a reaction bottle in this order, and the reaction was carried out at 110°C for 16 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction solution was directly rotovapped and purified by column chromatography to obtain N-(5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-yl)-1,1-diphenylmethanimine (A1-4, 59 mg, 43.9%). 1 H NMR (400 MHz, CDCl3) δ 8.82 (d, J = 9.7 Hz, 1H), 8.56 (s, 1H), 7.82 (d, J = 7.3 Hz, 2H), 7.74 (d, J = 1.8 Hz, 1H), 7.65 (dd, J = 8.4, 1.9 Hz, 1H), 7.57-7.49 (m, 1H), 7.43 (dt, J = 9.2, 5.8 Hz, 5H), 7.29 (m, 3H), 7.20 (d, J = 1.3 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 4.03 (s, 3H), 3.98 (s, 3H).

[0113] Fifth step: 5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-amine hydrochloride (A1-5) N-(5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-yl)-1,1-diphenylmethanimine (A1-4, 59 mg, 0.12mmol) was dissolved in tetrahydrofuran (10 mL), 1M hydrochloric acid (0.5 mL) was added dropwise to the reaction solution, and the mixture was reacted at room temperature for 4 hours. A white solid precipitated. The solid was collected by filtration and dried by heating to obtain 5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-amine hydrochloride (A1-5, 34 mg, 78.5%). 1H NMR (400 MHz, CDCl3) δ 8.83 (s, 1H), 8.74 (s, 1H), 7.77 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.33 (s, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.38 (s, 1H), 4.05 (s, 3H), 3.99 (s, 3H).

[0114] Sixth step: N-(5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-yl)pentanamide (A1) 5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-amine hydrochloride (A1-5, 32 mg, 0.09 mmol) was dissolved in dichloromethane (5 mL), cooled in an ice-water bath, triethylamine (18.5 mg, 0.183 mmol) was added, and pentanoic acid chloride (14.9 mg, 0.123 mmol) was dissolved in dichloromethane (0.5 mL) and added dropwise to the above system. Upon completion of the addition, the mixture was returned to room temperature and reacted for 16 hours, and the completion of the reaction was monitored by TLC. The reaction solution was dried by rotary evaporation as it was and purified by column chromatography to obtain N-(5-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiophen-3-yl)pentanamide (A1, 19 mg, 53.1%). 1H NMR (400 MHz, DMSO) δ 10.39 (s, 1H), 9.13 (s, 1H), 8.97 (s, 1H), 7.86 (d, J = 1.2 Hz, 1H), 7.80 (dd, J = 8.4, 1.9 Hz, 1H), 7.77 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 1.2 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 3.90 (s, 3H), 3.83 (d, J = 19.3 Hz, 3H), 2.32 (t, J = 7.4 Hz, 2H), 1.69-1.51 (m, 2H), 1.41-1.29 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H).

[0115] The preparation of compounds A2-A34 in Examples 2-34 was achieved by experimental procedures similar to those in Example 1 above, and compounds A1-A34 are summarized in Table 1. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7]

[0116] Example 35 Preparation of N-(5-(6-(4-(3-hydroxyoxetan-3-yl)-3-methoxyphenyl)pyrazin-2-yl)thiophen-3-yl)pentanamide (A35) (Method B) [ka]

[0117] First step: 3-(2-methoxy-4-pinacolboranyl-phenyl)oxetan-3-ol (A35-1) 3-(4-Bromo-2-methoxyphenyl)oxetan-3-ol (400 mg, 1.54 mmol), potassium acetate (379 mg, 3.86 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (57 mg, 0.08 mmol) and bis(pinacolato)diboron (471 mg, 1.85 mmol) were added to 1,4-dioxane (15 mL) and reacted at 80°C for 5 hours under nitrogen gas protection and monitored for completion by TLC. The reaction was filtered, the cake was washed with ethyl acetate, the reaction and washings were combined and spun to give 3-(2-methoxy-4-pinacolboranyl-phenyl)oxetan-3-ol (A35-1, crude, 1.54 mmol (theoretical value)), which was used directly in the next step reaction without any purification.

[0118] Second step: 3-(4-(6-bromopyrazin-2-yl)-2-methoxyphenyl)oxetan-3-ol (A35-2) 3-(2-Methoxy-4-pinacolboranyl-phenyl)oxetan-3-ol (A35-1, crude product, 1.54 mmol), potassium carbonate (512 mg, 3.70 mmol), 2,6-dibromopyrazine (551 mg, 2.32 mmol) and tetrakis(triphenylphosphine)palladium (89 mg, 0.08 mmol) were placed in 1,4-dioxane / water (4:1, 15 mL) and reacted at 80° C. for 5 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, 45 mL of water was added, and the mixture was extracted with EA (20 mL×3). The organic phases were combined, washed with saturated saline (20 mL×1), dried over anhydrous sodium sulfate, rotary dried, and purified by column chromatography to give 3-(4-(6-bromopyrazin-2-yl)-2-methoxyphenyl)oxetan-3-ol (A35-2, 310 mg, 59.6%). MS (ESI) m / z: calculated value 337.01 (M+H + ), actual value 337.00.

[0119] Third step: 3-(4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2-methoxyphenyl)oxetan-3-ol (A35-3) 3-(4-(6-bromopyrazin-2-yl)-2-methoxyphenyl)oxetane-3-ol (A35-2, 310 mg, 0.92 mmol), (4-bromothiophen-2-yl)boronic acid (191 mg, 0.93 mmol), tetrakis(triphenylphosphine)palladium (55 mg, 0.05 mmol) and potassium carbonate (305 mg, 2.21 mmol) were added to 1,4-dioxane / water (4:1, 15 mL) and reacted at 60°C for 0.5 hours under nitrogen gas protection, and the reaction was monitored for completion by TLC. The reaction solution was cooled to room temperature, 45 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL x 3), and the organic phase was combined, washed with saturated saline (20 mL x 1), dried over anhydrous sodium sulfate, and rotary evaporated. Purification by column chromatography gave 3-(4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2-methoxyphenyl)oxetan-3-ol (A35-3, 160 mg, 41.6%). MS (ESI) m / z: calculated 419.29 (M+H), found 419.00.

[0120] Fourth step: 3-(4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2-methoxyphenyl)oxetan-3-ol (A35-4) 3-(4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2-methoxyphenyl)oxetan-3-ol (A35-3, 160 mg, 0.38 mmol), cuprous iodide (15 mg, 0.08 mmol), L-proline (35 mg, 0.31 mmol), dimethyl sulfoxide (3 mL) and aqueous ammonia (25%wt, 360 mg, 2.57 mmol) were placed in a sealed tube in that order, sealed at 80°C and reacted for 10 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, 20 mL of water was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with saturated ammonium chloride (10 mL x 2), dried over anhydrous sodium sulfate, and rotary dried to obtain 3-(4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2-methoxyphenyl)oxetan-3-ol (A35-4, crude product, theoretical value 0.38 mmol), which was used in the next step reaction without any purification.

[0121] Fifth step: N-(5-(6-(4-(3-hydroxyoxetan-3-yl)-3-methoxyphenyl)pyrazin-2-yl)thiophen-3-yl)pentanamide (A35) 3-(4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2-methoxyphenyl)oxetan-3-ol (A35-4, crude product, 0.38 mmol) was dissolved in dichloromethane (10 mL), cooled in an ice-water bath, triethylamine (117 mg, 1.16 mmol) was added, pentanoic acid chloride (93 mg, 0.77 mol) was dissolved in dichloromethane (0.5 mL), and slowly added dropwise to the above system. When the addition was completed, the reaction was continued for 1 hour in an ice-water bath, and the completion of the reaction was monitored by TLC. The reaction solution was dried by rotary drying as it was, and then purified by column chromatography to obtain N-(5-(6-(4-(3-hydroxyoxetan-3-yl)-3-methoxyphenyl)pyrazin-2-yl)thiophen-3-yl)pentanamide (A35, 32 mg, 19.1%). MS (ESI) m / z: calcd 440.16 (M+H +), found 440.10. 1 H NMR (400 MHz, DMSO) δ 10.39 (s, 1H), 9.19 (s, 1H), 9.06 (s, 1H), 7.89 (d, J = 1.4 Hz, 1H), 7.76 (dd, J = 13.5, 7.3 Hz, 2H), 7.72 (d, J = 1.3 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 5.97 (s, 1H), 5.02 (d, J = 6.9 Hz, 2H), 4.67 (d, J = 6.9 Hz, 2H), 3.94 (d, J = 6.9 Hz, 3H), 2.36-2.29 (m, 2H), 1.64-1.56 (m, 2H), 1.38-1.30 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H).

[0122] Compounds A36-A45 in Examples 36-45 were prepared by experimental procedures similar to those in Example 35 above, and compounds A35-A45 are summarized in Table 2. [Table 2-1] [Table 2-2] [Table 2-3]

[0123] Example 46 Preparation of 2-Methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)-N-(1H-tetrazol-5-yl)benzamide (B4) [ka]

[0124] First step: 3-methoxy-4-methoxycarbonylphenylboronic acid pinacol ester (B4-1) Methyl 4-bromo-2-methoxybenzoate (10 g, 40.8 mmol), potassium acetate (10.1 g, 103 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (1.51 g, 2.06 mmol), bis(pinacolato)diboron (12.44 g, 49.0 mmol) and 1,4-dioxane (100 mL) were added in sequence to a reaction bottle, and the reaction was carried out at 80°C for 5 hours under nitrogen gas protection, and the completion of the reaction was monitored by TLC. The reaction solution was directly rotovapped and purified by column chromatography. 3-Methoxy-4-methoxycarbonylphenylboronic acid pinacol ester (B4-1, 11.0 g, 92.3%) was obtained. 1 H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 7.6 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.40 (s, 1H), 3.97 (s, 3H), 3.91 (s, 3H), 1.37 (s, 12H).

[0125] Second step: 2-methoxy-4-(6-bromopyrazin-2-yl)benzoic acid methyl ester (B4-2) 2,6-Dibromopyrazine (11.6 g, 48.8 mmol), 3-methoxy-4-methoxycarbonylphenylboronic acid pinacol ester (B4-1, 11.0 g, 37.6 mmol), potassium carbonate (13.52 g, 98.0 mmol), tetrakis(triphenylphosphine)palladium (2.37 g, 2.05 mmol), 1,4-dioxane (120 mL) and water (30 mL) were added in order to a reaction bottle, and the reaction was carried out at 100° C. for 5 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. Most of the 1,4-dioxane was removed by rotary evaporation, water (50 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, rotary evaporated, and purified by column chromatography to give 2-methoxy-4-(6-bromopyrazin-2-yl)benzoic acid methyl ester (B4-2, 6.67 g, 54.7%). MS (ESI) m / z: calculated value 323.00 (M+H + ), actual value 322.90; 1 H NMR (400 MHz, CDCl3) δ 9.00 (s, 1H), 8.68 (s, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.71 (d, J = 1.4 Hz, 1H), 7.59 (dd, J = 8.1, 1.6 Hz, 1H), 4.05 (s, 3H), 3.95 (s, 3H).

[0126] Third step: 2-Methoxy-4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B4-3) 2-Methoxy-4-(6-bromopyrazin-2-yl)benzoic acid methyl ester (B4-2, 6.67 g, 20.6 mmol), (4-bromothiophen-2-yl)boronic acid (4.30 g, 20.8 mmol), tetrakis(triphenylphosphine)palladium (1.3 g, 0.86 mmol), potassium carbonate (10.25 g, 74.3 mmol), 1,4-dioxane (120 mL) and water (30 mL) were added in order to a reaction bottle, and the reaction was carried out at 60° C. for 0.5 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction mixture was rotary evaporated to remove most of the 1,4-dioxane, and then dichloromethane (60 mL) and water (30 mL) were added, the aqueous phase was extracted with dichloromethane (30 mL x 2), the organic phase was combined, the organic phase was washed with saturated saline (30 mL x 1), dried over anhydrous sodium sulfate, rotary dried, and purified by column chromatography to obtain 2-methoxy-4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B4-3, 3.96 g, 47.3%). MS (ESI) m / z: calculated value 404.98 (M+H + ), actual value 404.90; 1 H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.90 (s, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.82 (s, 1H), 7.68 (d, J = 6.5 Hz, 1H), 7.44 (s, 1H), 6.98 (s, 1H), 4.08 (s, 3H), 3.96 (s, 3H).

[0127] Fourth step: 2-Methoxy-4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B4-4) 2-Methoxy-4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B4-3, 400 mg, 0.99 mmol), cuprous iodide (47 mg, 0.25 mmol), L-proline (57 mg, 0.50 mmol), dimethyl sulfoxide (25 mL) and aqueous ammonia (25%wt, 1.0 g, 5.92 mmol) were added in sequence to a sealed tube, sealed at 80°C and reacted for 10 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, water (100 mL) was added, and the mixture was extracted with ethyl acetate (40 mL x 3). The organic phases were combined, washed with saturated ammonium chloride (40 mL x 2), dried over anhydrous sodium sulfate, and rotovapped to obtain 2-methoxy-4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B4-4, 450 mg crude product, 0.99 mmol (theoretical value)), which was used directly in the next step reaction without any purification. MS (ESI) m / z: calculated value 342.08 (M+H + ), actual value 342.10.

[0128] Fifth step: 2-Methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B1) 2-Methoxy-4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B4-4, 450 mg crude product, 0.99 mmol (theoretical value)) was dissolved in dichloromethane (5 mL), cooled in an ice-water bath, triethylamine (666 mg, 6.59 mmol) was added, and pentanoic acid chloride (318 mg, 2.64 mmol) was dissolved in dichloromethane (1 mL) separately and added dropwise to the above system. After the addition was completed, the mixture was returned to room temperature and reacted for 0.5 hours, and the complete reaction was measured by TLC. The reaction solution was dried by rotation as it was and purified by column chromatography to obtain 2-methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B1, 295 mg, 70.0%). MS (ESI) m / z: Calculated value 426.14 (M+H +), actual value 426.10. 1 H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 9.27 (s, 1H), 9.13 (s, 1H), 7.91 (d, J = 3.2 Hz, 2H), 7.85 (s, 2H), 7.74 (s, 1H), 3.98 (s, 3H), 3.84 (s, 3H), 2.32 (t, J = 7.4Hz, 2H), 1.67-1.54 (m, 2H), 1.39-1.30(m, 2H), 0.92 (t, J = 7.3 Hz, 3H).

[0129] Sixth step: 2-Methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)benzoic acid (B2) 2-Methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (B1, 295 mg, 0.69 mmol), lithium hydroxide monohydrate (146 mg, 3.48 mmol), tetrahydrofuran (6 mL) and water (2 mL) were added to a reaction bottle in that order and reacted at room temperature for 16 hours. The reaction was monitored for completion by TLC. Tetrahydrofuran was removed by rotary evaporation, the mixture was diluted with 5 mL of water, acidified with 1 M hydrochloric acid to pH=3-4, extracted with ethyl acetate (10 mL×3), the organic phases were combined, washed with water, saturated brine, dried over anhydrous sodium sulfate, rotary evaporated and purified by column chromatography to give 2-methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)benzoic acid (B2, 258 mg, 90.4%). MS (ESI) m / z: Calculated value 412.13 (M+H + ), actual value 412.10.

[0130] Seventh step: 2-Methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)-N-(1H-tetrazol-5-yl)benzamide (B4) 2-Methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)benzoic acid (B4-6, 258 mg, 0.63 mmol), 5-aminotetrazole (56 mg, 0.66 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (241 mg, 1.26 mmol), 1-hydroxybenzotriazole (170 mg, 1.26 mmol), N,N-diisopropylethylamine (324 mg, 2.51 mmol) and N,N-dimethylformamide (5 mL) were added in sequence to a reaction bottle and reacted at room temperature for 16 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (20 mL x 3). The ethyl acetate phases were combined, and the organic phases were washed successively with water and saturated brine, dried over anhydrous sodium sulfate, rotary evaporated, and purified by column chromatography to give 2-methoxy-4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)-N-(1H-tetrazol-5-yl)benzamide (B4, 115 mg, 38.3%). MS (ESI) m / z: calculated value 477.15 (MH + ), actual value 477.10; 1 H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.29 (s, 1H), 9.13 (s, 1H), 8.05-7.82 (m, 3H), 7.73 (d, J = 1.3 Hz, 1H), 4.05 (s, 3H), 2.36-2.26 (m, 2H), 1.64-1.57(m, 2H), 1.44-1.28 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H).

[0131] Examples 47-121 (compounds B1-B78) were prepared by experimental procedures similar to those of Example 46 above, and compounds B1-B78 are summarized in Table 3. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12] [Table 3-13] [Table 3-14] [Table 3-15] [Table 3-16]

[0132] Example 122 Preparation of 3-(4-(cyclobutanecarboxamido)thiophen-2-yl)-5-(3,4-dimethoxyphenyl)isonicotinamide (C1) [ka]

[0133] First step: 3-bromo-5-(3,4-dimethoxyphenyl)isonicotinonitrile (C1-1) 3,5-Dibromo-4-cyanopyridine (1.5 g, 5.73 mmol), 3,4-dimethoxyphenylboronic acid (1.15 g, 6.30 mmol), tetrakis(triphenylphosphine)palladium (132 mg, 0.12 mmol), potassium carbonate (1.82 g, 13.17 mmol), 1,4-dioxane (20 mL) and water (4 mL) were placed in a reaction bottle and reacted at 80° C. for 14 hours under nitrogen gas protection, and the completion of the reaction was monitored by TLC. Most of the 1,4-dioxane was removed by rotary evaporation, the mixture was diluted with 25 mL of water, extracted with dichloromethane (15 mL × 2), the organic phases were combined, the organic phase was washed with saturated brine (15 mL × 1), dried over anhydrous sodium sulfate, and then rotary evaporated, and purified by column chromatography to give 3-bromo-5-(3,4-dimethoxyphenyl)isonicotinonitrile (C1-1, 676 mg, 37.0%). 1 H NMR (400 MHz, DMSO) δ 9.01 (s, 1H), 8.89 (s, 1H), 7.34 (d, J = 2.0 Hz, 1H), 7.26 (dd, J = 8.3, 2.0 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H).

[0134] Second step: 3-(4-bromothiophen-2-yl)-5-(3,4-dimethoxy)isonicotinonitrile (C1-2) 3-Bromo-5-(3,4-dimethoxyphenyl)isonicotinonitrile (C1-1, 470 mg, 1.47 mmol), (4-bromothiophen-2-yl)boronic acid (335.1 mg, 1.62 mmol), tetrakis(triphenylphosphine)palladium (34 mg, 0.029 mmol), potassium carbonate (610 mg, 4.42 mmol), 1,4-dioxane (10 mL) and water (2.5 mL) were placed in a reaction bottle and reacted at 80° C. for 14 hours under nitrogen gas protection, and the completion of the reaction was monitored by TLC. Most of the 1,4-dioxane was removed by rotary evaporation, the mixture was diluted with water (15 mL), extracted with dichloromethane (10 mL × 3), the organic phases were combined, the organic phase was washed with saturated brine (5 mL × 1), dried over anhydrous sodium sulfate, rotary evaporated, and then purified by column chromatography to give 3-(4-bromothiophen-2-yl)-5-(3,4-dimethoxyphenyl)isonicotinonitrile (C1-2, 190.5 mg, 30.8%). 1 H NMR (400 MHz, DMSO) δ 8.94 (s, 1H), 8.90 (s, 1H), 8.02 (d, J = 1.3 Hz, 1H), 7.77 (d, J = 1.4 Hz, 1H), 7.36 (d, J = 2.0 Hz, 1H), 7.29 (dd, J = 8.3, 2.0 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H).

[0135] Third step: 3-(3,4-dimethoxyphenyl)-5-(4-((diphenylmethylene)amino)thiophen-2-yl)isonicotinonitrile (C1-3) 3-(4-bromothiophen-2-yl)-5-(3,4-dimethoxy)isonicotinonitrile (C1-2, 100 mg, 0.238 mmol), benzophenone imine (64.83 mg, 0.358 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (29.70 mg, 0.048 mmol), tris(dibenzylideneacetone)dipalladium (21.84 mg, 0.024 mmol), sodium t-butoxide (68.76 mg, 0.715 mmol) and toluene (5 mL) were added to a reaction bottle in this order, and the reaction was carried out at 100°C for 16 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction solution was directly rotovapped and purified by column chromatography to obtain 3-(3,4-dimethoxyphenyl)-5-(4-((diphenylmethylene)amino)thiophen-2-yl)isonicotinonitrile (C1-3, 110 mg, 92.1%). 1 H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 8.69 (s, 1H), 7.82 (d, J = 6.2 Hz, 2H), 7.47-7.40 (m, 10H), 6.82 (d, J = 3.5 Hz, 1H), 6.77 (s, 1H), 6.65 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H).

[0136] Fourth step: 3-(4-aminothiophen-2-yl)-5-(3,4-dimethoxyphenyl)isonicotinonitrile hydrochloride (C1-4) 3-(3,4-dimethoxyphenyl)-5-(4-((diphenylmethylene)amino)thiophen-2-yl)isonicotinonitrile (C1-3, 110 mg, 0.219 mmol) was dissolved in dichloromethane, 2 drops of concentrated hydrochloric acid were added, and the mixture was reacted at room temperature for 4 hours. A white solid precipitated. The solid was collected by filtration and dried by heating to obtain 3-(4-aminothiophen-2-yl)-5-(3,4-dimethoxyphenyl)isonicotinonitrile hydrochloride (C1-4, 47 mg, 57.4%). MS (ESI) m / z: calculated value 338.09 (M+H +), actual value 338.10.

[0137] Fifth step: N-(5-(4-cyano-5-(3,4-dimethoxyphenyl)pyridin-3-yl)thiophen-3-yl)cyclobutanecarboxamide (C2) 3-(4-aminothiophen-2-yl)-5-(3,4-dimethoxyphenyl)isonicotinonitrile hydrochloride (C1-4, 30 mg, 0.08 mmol) was dissolved in 3 mL of dichloromethane, cooled in an ice-water bath, triethylamine (40.4 mg, 0.40 mmol) was added to the reaction system, and cyclobutane carboxylic acid chloride (11.61 mg, 0.098 mmol) was dissolved in dichloromethane (0.5 mL) and slowly added dropwise to the reaction system. After the addition was completed, the reaction was returned to room temperature and reacted for 3 hours, and the completion of the reaction was monitored by TLC. The reaction solution was dried by rotary evaporation as it was, and purified by column chromatography to obtain N-(5-(4-cyano-5-(3,4-dimethoxyphenyl)pyridin-3-yl)thiophen-3-yl)cyclobutanecarboxamide (C2, 32 mg, 95%). 1 H NMR (400 MHz, CDCl3) δ 8.88 (s, 1H), 8.75 (s, 1H), 7.91 (s, 1H), 7.61 (s, 1H), 7.48 (s, 1H), 7.19 (dd, J = 8.3, 2.0 Hz, 1H), 7.14 (d, J = 1.9 Hz, 1H), 7.06 (d, J = 8.3 Hz, 1H), 3.99 (s, 6H), 3.25-3.13 (m, 1H), 2.51-2.37 (m, 2H), 2.31-2.25 (m, 2H).

[0138] Sixth step: 3-(4-(cyclobutanecarboxamido)thiophen-2-yl)-5-(3,4-dimethoxyphenyl)isonicotinamide (C1) N-(5-(4-cyano-5-(3,4-dimethoxyphenyl)pyridin-3-yl)thiophen-3-yl)cyclobutanecarboxamide (C2, 2 mg, 0.0048mmol), sodium t-butoxide (1.68 mg, 0.015 mmol) and t-butanol (3 mL) were added to a reaction bottle, and the temperature was raised to 50°C for 2 hours. The reaction was monitored for completion by TLC. The reaction was cooled to room temperature, and ice water (10 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (5 mL x 3), and the organic phases were combined. The organic phase was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and rotary dried to give 3-(4-(cyclobutanecarboxamide)thiophen-2-yl)-5-(3,4-dimethoxyphenyl)isonicotinamide (C1, 1.8 mg, ). 1 H NMR (400 MHz, CDCl3) δ 8.74 (s, 1H), 8.64 (s, 1H), 7.78 (s, 1H), 7.60 (s, 1H), 7.12 (d, J = 1.5 Hz, 1H), 7.09 (dd, J = 8.0, 1.7 Hz, 1H), 6.97 (d, J = 8.3 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.20-3.12 (m, 1H), 2.44-2.36 (m, 2H), 2.28-2.20 (m, 2H).

[0139] Examples 123-124 were prepared by experimental procedures similar to those of Example 122 above, and compounds C1-C4 are summarized in Table 4. [Table 4-1] [Table 4-2]

[0140] Example 125 Preparation of N-(4-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)cyclohexyl)cyclobutanecarboxamide (D2) [ka]

[0141] First step: N 1 -(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)cyclohexane-1,4-diamine (D1) 2-Bromo-6-(3,4-dimethoxyphenyl)pyrazine (A1-2, 50 mg, 0.17 mmol), 1,4-cyclohexanediamine (97 mg, 0.85 mmol), sodium t-butoxide (33 mg, 0.34 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (10.6 mg, 0.017 mmol), tris(dibenzylideneacetone)dipalladium (7.3 mg, 0.008 mmol) and toluene (10 mL) were added to a reaction bottle in that order, and the reaction was carried out at 110 °C for 4 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction solution was cooled to room temperature, the solvent was removed by rotary evaporation, and the product was purified by column chromatography and purified with N. 1 -(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)cyclohexane-1,4-diamine (D1, 25 mg, 45.0%) was obtained. 1 H NMR (400 MHz, DMSO) δ 8.23 ​​(s, 1H), 7.78 (s, 1H), 7.64 (s, 1H), 7.61 (d, J = 8.3 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 7.0 Hz, 1H), 3.84 (s, 3H), 3.81 (s, 3H), 3.04 (dt, J = 13.9, 7.0 Hz, 2H), 2.05 (s, 2H), 1.87 (s, 2H), 1.26 (s, 4H).

[0142] Second step: N-(4-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)cyclohexyl)cyclobutanecarboxamide (D2) N 1-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)cyclohexane-1,4-diamine (D1, 14 mg, 0.043 mmol) was dissolved in dichloromethane (5 mL) and cyclobutanecarboxylic acid chloride (6.1 mg, 0.051 mmol) was added and reacted at room temperature for 2 hours. The reaction was monitored for completion by TLC. The reaction was quenched by adding water (10 mL), separated, the aqueous phase was extracted with dichloromethane (5 mL), the organic phase was combined, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, rotary evaporated, and purified by column chromatography to give N-(4-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)cyclohexyl)cyclobutanecarboxamide (D2, 8 mg, 45.3%). MS (ESI) m / z: calculated value 411.23 (M+H + ), actual value 411.57; 1 H NMR (400 MHz, CDCl3) δ 8.26 (s, 1H), 7.80 (s, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.55 (dd, J = 8.3, 1.9 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 5.20 (d, J = 7.6 Hz, 1H), 4.70 (s, 1H), 4.00 (s, 3H), 3.96 (s, 3H), 3.37-3.26 (m, 1H), 3.03-2.94 (m, 1H), 2.34-2.31 (m, 4H), 2.21-2.07 (m, 4H), 1.93-1.86 (m, 1H), 1.35-1.22 (m, 4H), 0.96-0.77 (m, 2H).

[0143] Example 126 Preparation of 3-(2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazol-4-yl)-1,1-diethylurea (D4) [ka]

[0144] First step: 6-(3,4-dimethoxyphenyl)pyrazine-2-carbonitrile (D4-1) 2-Bromo-6-(3,4-dimethoxyphenyl)pyrazine (A1-2, 520 mg, 1.76mmol), cuprous cyanide (189 mg, 2.11 mmol) and N-methylpyrrolidone (14 mL) were added to a reaction bottle in that order and reacted at 180°C for 1 hour, and the completion of the reaction was monitored by TLC. The reaction solution was cooled to room temperature, diluted with water (70 mL), extracted with ethyl acetate (30 mL x 3), and the organic phase was combined. The organic phase was washed with water and saturated saline in that order and dried over anhydrous sodium sulfate to obtain 6-(3,4-dimethoxyphenyl)pyrazine-2-carbonitrile (D4-1, 268 mg, 63.1%). 1 H NMR (400 MHz, DMSO) δ 9.58 (s, 1H), 9.09 (s, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.73 (s, 1H), 7.16 (d, J = 8.5 Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H).

[0145] Second step: 6-(3,4-dimethoxyphenyl)pyrazine-2-carboxamide (D4-2) 6-(3,4-dimethoxyphenyl)pyrazine-2-carbonitrile (D4-1, 268 mg, 1.11 mmol) was dissolved in trifluoroacetic acid / concentrated sulfuric acid (4 / 1, 10 mL) and reacted at 50° C. for 3 hours, and the completion of the reaction was monitored by TLC. The reaction solution was cooled in an ice-water bath and basified with 2 M sodium hydroxide solution to pH=8-11, and a solid precipitated. The solid was collected by filtration and dried by heating to obtain 6-(3,4-dimethoxyphenyl)pyrazine-2-carboxamide (D4-2, 201 mg, 69.8%). 1 H NMR (400 MHz, DMSO) δ 9.44 (s, 1H), 9.04 (s, 1H), 8.48 (s, 1H), 8.07-7.87 (m, 3H), 7.12 (d, J = 8.4 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H).

[0146] Third step: 6-(3,4-dimethoxyphenyl)pyrazine-2-thiocarboxamide (D4-3) 6-(3,4-dimethoxyphenyl)pyrazine-2-carboxamide (D4-2, 201 mg, 0.775 mmol), Lawesson's reagent (188 mg, 0.465 mmol) and acetonitrile (10 mL) were added to a reaction bottle and reacted at 80° C. for 16 h and monitored for completion by TLC. The reaction was cooled to room temperature, rotovapped and purified by column chromatography to give 6-(3,4-dimethoxyphenyl)pyrazine-2-thiocarboxamide (D4-3, 157 mg, 73.5%). 1 H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 10.18 (s, 1H), 9.44 (d, J = 6.2 Hz, 2H), 8.09-7.83 (m, 2H), 7.11 (d, J = 8.5 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H).

[0147] Fourth step: 2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazole-4-carboxylic acid methyl ester (D4-4) 6-(3,4-Dimethoxyphenyl)pyrazine-2-thiocarboxamide (D4-3, 142 mg, 0.52 mmol), methyl bromopyruvate (140 mg, 0.62 mmol) and methanol (15 mL) were added in sequence to a reaction bottle and reacted at 70°C for 16 hours, and the reaction completion was monitored by TLC. The reaction solution was cooled to room temperature, and a solid precipitated. The solid was collected by filtration and dried by heating to obtain 2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazole-4-carboxylic acid methyl ester (D4-4, 82 mg, 44.1%). 1H NMR (400 MHz, DMSO) δ 9.42 (s, 1H), 9.20 (s, 1H), 8.80 (s, 1H), 7.87 (dd, J = 8.5, 1.9 Hz, 1H), 7.82 (d, J = 1.9 Hz, 1H), 7.18 (d, J = 8.5 Hz, 1H), 3.92 (s, 6H), 3.87 (s, 3H).

[0148] Fifth step: 2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazole-4-carboxylic acid (D4-5) 2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazole-4-carboxylic acid methyl ester (D4-4, 80 mg, 0.224 mmol), lithium hydroxide monohydrate (47 mg, 1.12 mmol) and tetrahydrofuran / water (3 / 1, 4 mL) were added to a reaction bottle in that order and reacted at 40°C for 2 hours, and the reaction completion was monitored by TLC. The reaction solution was cooled in an ice-water bath, acidified with 2 M hydrochloric acid, and adjusted to pH=3-4, and a solid precipitated. The solid was filtered, collected and dried by heating to obtain 2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazole-4-carboxylic acid (D4-5, 75.0 mg, 97.5%). 1 H NMR (400 MHz, DMSO) δ 9.41 (s, 1H), 9.19 (s, 1H), 8.70 (s, 1H), 7.87 (dd, J = 8.4, 1.9 Hz, 1H), 7.82 (d, J = 1.9 Hz, 1H), 7.18 (d, J = 8.5 Hz, 1H), 3.92 (s, 3H), 3.87 (s, 3H).

[0149] Sixth step: (2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazol-4-yl)carbamic acid t-butyl ester (D3) 2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazole-4-carboxylic acid (D4-5, 50.0 mg, 0.146 mmol), triethylamine (44.3 mg, 0.438 mmol) and t-butanol (5 mL) were added in a reaction bottle in that order, and diphenylphosphoryl azide (80.1 mg, 0.292 mmol, diluted with 0.5 mL t-butanol) was added dropwise. After the addition was completed, the temperature was raised to 85°C and the reaction was carried out for 16 hours, and the completion of the reaction was monitored by TLC. The reaction solution was rotovapped and purified by column chromatography to obtain (2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazole-4-yl)carbamic acid t-butyl ester (D3, 25 mg, 41.3%). 1 H NMR (400 MHz, CDCl3) δ 9.20 (s, 1H), 9.02 (s, 1H), 7.77 (d, J = 1.9 Hz, 1H), 7.73-7.61 (m, 2H), 7.47 (s, 1H), 7.04 (d, J = 8.4 Hz, 1H), 4.06 (s, 3H), 4.00 (s, 3H), 1.59 (s, 9H).

[0150] Seventh step: 3-(2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazol-4-yl)-1,1-diethylurea (D4) (2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazol-4-yl)carbamic acid t-butyl ester (D3, 18 mg, 0.043 mmol) and hydrogen chloride in ethyl acetate (3 M, 5 mL) were added to a reaction bottle in that order, and the mixture was reacted at room temperature for 1 hour. A solid precipitated, and the solid was collected by filtration. The solid was transferred to a reaction bottle and dissolved in dichloromethane (2 mL) and triethylamine (27.3 mg, 0.27 mmol). Separately, N,N-diethylchlorocarboxamide (14.9 mg, 0.11 mmol) was dissolved in dichloromethane (0.5 mL) and added dropwise to the above system. After the addition was completed, the mixture was allowed to react at room temperature for 2 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was then spun down and purified by column chromatography to give 3-(2-(6-(3,4-dimethoxyphenyl)pyrazin-2-yl)thiazol-4-yl)-1,1-diethylurea (D4, 0.8 mg, 4.5%). MS (ESI) m / z: calculated 414.15 (M+H + ), actual value 414.10; 1 H NMR (400 MHz, CDCl3) δ 9.16 (s, 1H), 9.01 (s, 1H), 7.77 (d, J = 1.9 Hz, 1H), 7.70 (dd, J = 8.3, 1.9 Hz, 1H), 7.64 (s, 1H), 7.44 (s, 1H), 7.04 (d, J = 8.4 Hz, 1H), 4.06 (s, 3H), 4.00 (s, 3H), 3.46 (q, J = 7.2 Hz, 4H), 1.31 (t, J = 7.2 Hz, 6H).

[0151] Example 127 Preparation of 2-methoxy-4-(4-(4-pentanamidothiophene)pyrimidin-2-yl)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (D5) [ka]

[0152] First step: 2-bromo-4-(4-bromothiophen-2-yl)pyrimidine (D5-1) 2,4-Dibromopyrimidine (100 mg, 0.42 mmol), (4-bromothiophen-2-yl)boronic acid (87 mg, 0.42 mmol), tetrakis(triphenylphosphine)palladium (24 mg, 0.021 mmol), potassium carbonate (87 mg, 0.63 mmol), 1,4-dioxane (1.6 mL) and water (0.4 mL) were reacted under nitrogen gas protection at 80° C. for 4 hours and the reaction completion was monitored by TLC. The reaction solution was rotovapped and then purified by column chromatography to give 2-bromo-4-(4-bromothiophen-2-yl)pyrimidine (D5-1, 90 mg, 67.0%). MS (ESI) m / z: calculated value 318.85 (M+H + ), actual value 318.90.

[0153] Second step: 4-(4-(4-bromothiophen-2-yl)pyrimidin-2-yl)-2-methoxybenzoic acid methyl ester (D5-2) 2-Bromo-4-(4-bromothiophen-2-yl)pyrimidine (D5-1, 90 mg, 0.28 mmol), 3-methoxy-4-methoxycarbonylphenylboronic acid pinacol ester (B4-1, 98 mg, 0.34 mmol), tetrakis(triphenylphosphine)palladium (32 mg, 0.028 mmol), potassium carbonate (58 mg, 0.42 mmol), 1,4-dioxane (2 mL) and water (0.5 mL) were reacted under nitrogen gas protection at 80°C for 2 hours and the reaction completion was monitored by TLC. The reaction solution was dried by rotary evaporation and purified by column chromatography to obtain 4-(4-(4-bromothiophen-2-yl)pyrimidin-2-yl)-2-methoxybenzoic acid methyl ester (D5-2, 101 mg, 88.9%). 1H NMR (400 MHz, DMSO) δ 9.00 (d, J = 5.3 Hz, 1H), 8.27 (s, 1H), 8.15 (s, 1H), 8.08 (d, J = 8.1 Hz, 1H), 8.04 (d, J = 6.7 Hz, 2H), 7.84 (d, J = 8.0 Hz, 1H), 3.96 (s, 3H), 3.84 (s, 3H).

[0154] Third step: 4-(4-(4-aminothiophen-2-yl)pyrimidin-2-yl)-2-methoxybenzoic acid methyl ester (D5-3) 4-(4-(4-bromothiophen-2-yl)pyrimidin-2-yl)-2-methoxybenzoic acid methyl ester (D5-2, 100 mg, 0.247mmol), cuprous iodide (9.4 mg, 0.049 mmol), L-proline (11.4 mg, 0.10 mmol), dimethyl sulfoxide (2 mL) and aqueous ammonia (25%wt, 200 mg, 1.48 mmol) were placed in a sealed tube in that order, sealed at 80°C and reacted for 16 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, water (10 mL) was added, and the mixture was extracted with ethyl acetate (5 mL x 3). The organic phases were combined, washed with saturated ammonium chloride (5 mL x 4), dried over anhydrous sodium sulfate, and rotovapped to obtain 4-(4-(4-aminothiophen-2-yl)pyrimidin-2-yl)-2-methoxybenzoic acid methyl ester (D5-3, 105 mg crude product, 0.247 mmol (theoretical value)), which was used in the next step reaction without any purification. MS (ESI) m / z: calculated value 342.08 (M+H + ), actual value 342.10.

[0155] Fourth step: 2-Methoxy-4-(4-(4-pentanamidothiophen-2-yl)pyrimidin-2-yl)benzoic acid methyl ester (D5-4) 4-(4-(4-aminothiophen-2-yl)pyrimidin-2-yl)-2-methoxybenzoic acid methyl ester (D5-3, 105 mg crude product, 0.247 mmol (theoretical value)) was dissolved in dichloromethane (5 mL), cooled in an ice-water bath, triethylamine (31 mg, 0.31 mmol) was added, and pentanoic acid chloride (56 mg, 0.46 mmol) was dissolved in dichloromethane (1 mL) separately and added dropwise to the above system. After the addition was completed, the mixture was returned to room temperature and reacted for 0.5 hours, and the complete reaction was measured by TLC. The reaction solution was dried by rotary drying as it was and purified by column chromatography to obtain 2-methoxy-4-(4-(4-pentanamidothiophen-2-yl)pyrimidin-2-yl)benzoic acid methyl ester (D5-4, 67 mg, 63.8%). MS (ESI) m / z: Calculated value 426.14 (M+H + ), actual value 426.10.

[0156] Fifth step: 2-Methoxy-4-(4-(4-pentanamidothiophen-2-yl)pyrimidin-2-yl)benzoic acid (D5-5) 2-Methoxy-4-(4-(4-pentanamidothiophen-2-yl)pyrimidin-2-yl)benzoic acid methyl ester (D5-4, 67 mg, 0.158 mmol), lithium hydroxide monohydrate (33 mg, 0.786 mmol), tetrahydrofuran (4 mL) and water (1 mL) were added to a reaction bottle in that order and reacted at room temperature for 16 hours. The reaction was monitored for completion by TLC. Tetrahydrofuran was removed by rotary evaporation, and the mixture was diluted with water (5 mL), acidified with saturated citric acid to pH=3-4, extracted with ethyl acetate (10 mL×3), and the organic phases were combined. The organic phase was washed with water, saturated brine, dried over anhydrous sodium sulfate, rotary evaporated, and purified by column chromatography to give 2-methoxy-4-(4-(4-pentanamidothiophen-2-yl)pyrimidin-2-yl)benzoic acid (D5-5, 56 mg, 86.1%). MS (ESI) m / z: Calculated value 412.13 (M+H + ), actual value 412.10.

[0157] Sixth step: 2-Methoxy-4-(4-(4-pentanamidothiophene)pyrimidin-2-yl)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (D5) 2-Methoxy-4-(4-(4-pentanamidothiophen-2-yl)pyrimidin-2-yl)benzoic acid (D5-5, 10 mg, 0.024 mmol), 1-methyl-4-(methylamino)piperidine (4.7 mg, 0.036 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (9.3 mg, 0.048 mmol), 1-hydroxybenzotriazole (6.6 mg, 0.048 mmol), N,N-diisopropylethylamine (9.4 mg, 0.073 mmol) and N,N-dimethylformamide (1 mL) were added in sequence to a reaction bottle and reacted at room temperature for 5 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (5 mL x 3). The organic phases were combined and washed with water and saturated brine, dried over anhydrous sodium sulfate, rotovapped, and purified by column chromatography to give 2-methoxy-4-(4-(4-pentanamidothiophene)pyrimidin-2-yl)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (D5, 5 mg, 39.4%). MS (ESI) m / z: calculated value 522.25 (M+H + ), actual value 522.40; 1H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 8.92 (dd, J = 5.3, 2.2 Hz, 1H), 8.16 - 8.06 (m, 2H), 8.01 (dd, J = 5.6, 1.4 Hz, 1H), 7.84 (dd, J = 5.3, 2.6 Hz, 1H), 7.78 (dd, J = 3.2, 1.3 Hz, 1H), 7.38 (dd, J = 10.3, 8.2 Hz, 1H), 3.93 (s, 3H), 3.52 (d, J = 8.0 Hz, 2H), 3.19 (d, J = 12.6 Hz, 2H), 2.99 (s, 1H), 2.92-2.79 (m, 3H), 2.66 (d, J = 7.1 Hz, 3H), 2.32 (t, J = 7.4 Hz, 2H), 2.08-1.77 (m, 4H), 1.60 (dt, J = 15.0, 7.5 Hz, 2H), 1.34 (dq, J = 14.5, 7.3 Hz, 2H), 0.91 (t, J = 7.3 Hz, 3H).

[0158] Example 128 Preparation of N-(5-(6-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide (D6) [ka]

[0159] First step: 4-(6-bromopyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (D6-1) Piperazine-1-carboxylic acid t-butyl ester (300 mg, 1.61 mmol), 2,6-dibromopyrazine (460 mg, 1.93 mmol), potassium carbonate (445 mg, 3.22 mmol), and dimethyl sulfoxide (9 mL) were reacted at 120 °C for 5 h under nitrogen gas protection, and the reaction was monitored for completion by TLC. The reaction was cooled to room temperature, added to 50 mL of water, extracted with ethyl acetate (20 mL x 3), the combined organic phase was washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, and rotary evaporated to give 4-(6-bromopyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (D6-1, 250 mg, 45.2%). MS (ESI) m / z: calculated 343.07 (M+H), found 343.10.

[0160] Second step: 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (D6-2) 4-(6-bromopyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (250 mg, 0.73 mmol), (4-bromothiophen-2-yl)boronic acid (200 mg, 0.97 mmol), tetrakis(triphenylphosphine)palladium (42 mg, 0.036 mmol), potassium carbonate (242 mg, 1.75 mmol) and 1,4-dioxane / water (4:1, 15 mL) were added to a reaction bottle in that order, and the reaction was carried out at 60° C. for 0.5 hours under the protection of nitrogen gas, and the reaction completion was monitored by TLC. Water (25 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL×3), and the organic phase was combined, washed with saturated saline, dried over anhydrous sodium sulfate, and rotary evaporated. Purification by column chromatography gave 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid tert-butyl ester (D6-2, 105 mg, 33.8%). 1H NMR (400 MHz, DMSO) δ 8.46 (s, 1H), 8.26 (s, 1H), 7.91 (d, J = 1.3 Hz, 1H), 7.81 (d, J = 1.3 Hz, 1H), 3.64-3.60 (m, 4H), 3.48-3.45 (m, 4H), 1.44 (s, 9H).

[0161] Third step: 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (D6-3) 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (105 mg, 0.25 mmol), cuprous iodide (10 mg, 0.052 mmol), L-proline (23 mg, 0.2 mmol), dimethyl sulfoxide (2 mL) and aqueous ammonia (25%wt, 59 mg, 1.69 mmol) were placed in a sealed tube in that order, sealed at 80°C and reacted for 16 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, water (10 mL) was added, and the mixture was extracted with ethyl acetate (5 mL×3). The organic phases were combined, washed with saturated ammonium chloride (5 mL×2), dried over anhydrous sodium sulfate, and rotovapped to give 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid tert-butyl ester (D6-3, 90 mg, 0.25 mmol (theoretical value)), which was used in the next step without any purification. MS (ESI) m / z: calculated 362.16 (M+H), found 362.10.

[0162] Fourth step: 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (D6-4) 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (D6-3, 90 mg, 0.25 mmol (theoretical value)) was dissolved in dichloromethane (5 mL), cooled in an ice-water bath, triethylamine (76 mg, 0.75 mmol) was added, and pentanoic acid chloride (60 mg, 0.498 mmol) was separately dissolved in dichloromethane (0.5 mL) and slowly added dropwise to the above reaction system, reacted in an ice-water bath for 1 hour, monitored for completion of the reaction by TLC, and purified by column chromatography to obtain 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (D6-4, 65 mg, 58.3%). MS (ESI) m / z: Calculated value 446.21 (M+H + ), actual value 446.30.

[0163] Fifth step: N-(5-(6-(piperazin-1-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide (D6-5) 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)piperazine-1-carboxylic acid t-butyl ester (65 mg, 0.146 mmol) was dissolved in methanol (1 mL) and a solution of hydrogen chloride in methanol (3 M, 1 mL) was added to the system and reacted at room temperature for 16 hours. Completion of the reaction was monitored by TLC, and the reaction solution was rotovapped and carried on to the next step without any treatment to give N-(5-(6-(piperazin-1-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide (D6-5, 0.146 mmol (theoretical value)). MS (ESI) m / z: calculated value 346.21 (M+H + ), actual value 346.30.

[0164] Sixth step: N-(5-(6-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide (D6) N-(5-(6-(piperazin-1-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide (D6-5, 0.146 mmol (theoretical value)) was dissolved in dichloromethane (5 mL), cooled in an ice-water bath, triethylamine (73 mg, 0.72 mmol) was added, and methanesulfonyl chloride (25 mg, 0.22 mmol) was dissolved in dichloromethane (0.5 mL) separately and slowly added dropwise to the above system. When the addition was completed, the temperature was returned to room temperature and reacted for 0.5 hours. The completion of the reaction was monitored by TLC, and the reaction solution was dried by rotation as it was, and then purified by column chromatography to obtain N-(5-(6-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide (D6, 21 mg, 34.0%). MS (ESI) m / z: Calculated value 423.55 (M+H +), Actual value 424.30;1H NMR (400 MHz, DMSO) δ 10.31 (s, 1H), 8.31 (s, 1H), 8.27 (s, 1H), 7.69 (d, J = 1.4 Hz, 1H), 7.62 (s, 1H), 3.77 (s, 4H), 3.26 (d, J = 4.9 Hz, 4H), 2.92 (s, 3H), 2.31 - 2.27 (m, 2H), 1.58 (d, J = 7.4 Hz, 2H), 1.35-1.30 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H).

[0165] Example 129 Preparation of N-(5-(6-(1-(methylsulfonyl)piperidin-4-yl)pyrazin-2yl)thiophen-3-yl)pentanamide (D7) [ka]

[0166] First step: 4-(6-bromopyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid t-butyl ester (D7-1) N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (500 mg, 1.62 mmol), 2,6-dibromopyrazine (385 mg, 1.62 mmol), sodium carbonate (429 mg, 4.05 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (60 mg, 0.082 mmol) and 1,4-dioxane / water (5:1, 12 mL) were added to a reaction bottle in that order, and the reaction was carried out at 100°C for 5 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction solution was dried by rotation as it was, and then purified by column chromatography to obtain 4-(6-bromopyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid t-butyl ester (D7-1, 310 mg, 56.3%). 1H NMR (400 MHz, DMSO) δ 8.88 (s, 1H), 8.72 (s, 1H), 6.88 (s, 1H), 4.10 (d, J = 2.3 Hz, 2H), 3.60-3.49 (m, 2H), 2.54 (d, J = 1.7 Hz, 2H), 1.43 (s, 9H).

[0167] Second step: 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid t-butyl ester (D7-2) 4-(6-bromopyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid t-butyl ester (D7-1, 220 mg, 0.647 mmol), (4-bromothiophen-2-yl)boronic acid (134 mg, 0.647 mmol), tetrakis(triphenylphosphine)palladium (75 mg, 0.065 mmol), potassium carbonate (214 mg, 1.75 mmol) and 1,4-dioxane / water (5:1, 6 mL) were added to a reaction bottle in that order, and the reaction was carried out at 60° C. for 0.5 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction mixture was poured into water (25 mL) and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, rotary evaporated, and purified by column chromatography to obtain 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (D7-2, 158 mg, 57.8%). 1 H NMR (400 MHz, DMSO) δ 9.12 (s, 1H), 8.78 (s, 1H), 8.07 (d, J = 1.4 Hz, 1H), 7.89 (d, J = 1.4 Hz, 1H), 6.90 (s, 1H), 4.12 (s, 2H), 3.66-3.52 (m, 3H), 2.62 (s, 2H), 1.44 (s, 9H).

[0168] Third step: t-butyl 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (D7-3) 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid t-butyl ester (D7-2, 158 mg, 0.375 mmol), cuprous iodide (14 mg, 0.074 mmol), L-proline (17 mg, 0.148 mmol), dimethyl sulfoxide (2 mL) and aqueous ammonia (25%wt, 315 mg, 2.25 mmol) were added in sequence to a sealed tube, sealed at 80°C and reacted for 16 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, water (10 mL) was added, and the mixture was extracted with ethyl acetate (5 mL x 3). The organic phases were combined, washed with saturated ammonium chloride (5 mL x 2), dried over anhydrous sodium sulfate, and rotovapped to obtain tert-butyl 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (D7-3, 0.375 mmol (theoretical value)), which was used in the next step reaction without any purification. MS (ESI) m / z: calculated value 359.15 (M+H + ), actual value 359.10.

[0169] Fourth step: 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid t-butyl ester (D7-4) 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate t-butyl (D7-3, 0.375 mmol (theoretical value)) was dissolved in dichloromethane (5 mL), cooled in an ice-water bath, triethylamine (73 mg, 0.72 mmol) was added, and pentanoic acid chloride (134 mg, 1.11 mmol) was dissolved in dichloromethane (0.5 mL) separately and slowly added dropwise to the above system. Upon completion of the addition, the mixture was returned to room temperature and reacted for 0.5 hours. The completion of the reaction was monitored by TLC, and the reaction solution was dried by rotary drying as it was, and then purified by column chromatography to obtain 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate t-butyl ester (D7-4, 35 mg, 21.1%). MS (ESI) m / z: Calculated value 443.20 (M+H + ), actual value 443.10.

[0170] Fifth step: 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)piperidine-1-carboxylic acid t-butyl ester (D7-5) 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid t-butyl ester (D7-4, 35 mg, 0.079 mmol) was dissolved in methanol (2 mL), palladium on carbon (35 mg) was added, and the mixture was reacted at room temperature for 16 hours under hydrogen gas (1 atm) atmosphere, and the reaction was monitored for completion by TLC. The palladium on carbon was removed by filtration, and the mixture was dried by rotation to obtain 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)piperidine-1-carboxylic acid t-butyl ester (D7-5, 35 mg, 100%). MS (ESI) m / z: calculated value 445.22 (M+H + ), actual value 445.20.

[0171] Sixth step: N-(5-(6-(piperidin-4-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide hydrochloride (D7-6) 4-(6-(4-pentanamidothiophen-2-yl)pyrazin-2-yl)piperidine-1-carboxylic acid t-butyl ester (D7-5, 35 mg, 0.079 mmol) was dissolved in methanol (4 mL), and a solution of hydrogen chloride in methanol (3 M, 4 mL) was added and reacted at room temperature for 1 hour. The reaction was monitored for completion by LCMS, and the mixture was spun dry and used directly in the next step to give N-(5-(6-(piperidin-4-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide hydrochloride (D7-6, 30 mg, 100%). MS (ESI) m / z: calculated value 345.17 (M+H + ), actual value 345.10.

[0172] Seventh step: N-(5-(6-(1-(methylsulfonyl)piperidin-4-yl)pyrazin-2yl)thiophen-3-yl)pentanamide (D7) N-(5-(6-(piperidin-4-yl)pyrazin-2-yl)thiophen-3-yl)pentanamide hydrochloride (D7-6, 30 mg, 0.079 mmol) was dissolved in dichloromethane (5 mL), triethylamine (24 mg, 0.238 mmol) was added, and the temperature was lowered in an ice-water bath. Separately, methanesulfonyl chloride (13.6 mg, 0.119 mmol) was dissolved in dichloromethane (2 mL) and added dropwise to the above system. Upon completion of the addition, the temperature was returned to room temperature and reacted for 0.5 hours, and the completion of the reaction was monitored by LCMS. The reaction solution was dried by rotary drying as it was, and then purified by column chromatography to obtain N-(5-(6-(1-(methylsulfonyl)piperidin-4-yl)pyrazin-2yl)thiophen-3-yl)pentanamide (D7, 1.6 mg, 4.8%). MS (ESI) m / z: Calculated value 423.14 (M+H + ), actual value 423.10; 1H NMR (400 MHz, DMSO) δ 10.35 (s, 1H), 8.94 (s, 1H), 8.51 (d, J = 3.7 Hz, 1H), 7.81 (d, J = 1.4 Hz, 1H), 7.66 (d, J = 1.3 Hz, 1H), 3.70 (d, J = 11.9 Hz, 2H), 3.01-2.83 (m, 5H), 2.34-2.28 (m, 2H), 2.08-2.01 (m, 2H), 1.88-1.77 (m, 2H), 1.63-1.55 (m, 2H), 1.38-1.30 (m, 2H), 1.24 (s, 1H), 0.91 (t, J = 7.3 Hz, 3H).

[0173] Example 130 was prepared by experimental procedures similar to those of Examples 123-129 above, and compounds D1-D8 are summarized in Table 5. [Table 5-1] [Table 5-2]

[0174] Examples 131-152 (compounds B79-100) were prepared by experimental procedures similar to those of Example 46 above, and compounds B79-100 are summarized in Table 6. [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4] [Table 6-5] [Table 6-6] [Table 6-7] [Table 6-8] [Table 6-9] [Table 6-10]

[0175] Example 155 Preparation of 2-cyclopropyl-N-(5-(6-(3-methoxy-4-(N-methyl-N-(1-methylpiperidin-4-yl)sulfamoyl)phenyl)pyrazin-2-yl)thiophen-3-yl)acetamide (B103) [ka]

[0176] First step: 4-bromo-2-methoxybenzenesulfonyl chloride (B103-1) Cuprous chloride (20 mg, 0.20 mmol) was dissolved in water (30 mL), and the reaction system was cooled to 0-10°C in an ice-water bath. Thionyl chloride (8.0 g, 67.24 mmol) was slowly added dropwise to the reaction system, and the system was allowed to return to room temperature naturally. The reaction was continued for 16 hours to form stable system A. 2-Methoxy-4-bromoaniline (3.0 g, 14.85 mmol) was dissolved in acetic acid (15 mL), and the system was allowed to cool to about 10°C in an ice-water bath. Separately, sodium nitrite (1.12 g, 16.23 mmol) was dissolved in water (5 mL) and added dropwise to the reaction system. After the addition was completed, the reaction was continued at 0°C for 1 hour to form stable system B. The temperature of stable system A was lowered to 0-10°C, and stable system B was slowly added dropwise to A. After the addition was completed, the mixture was allowed to return to room temperature and reacted for 16 hours, and the completion of the reaction was detected by TLC. The reaction system was extracted with ethyl acetate (50 mL x 3), the organic phase was combined, the organic phase was washed with saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and rotary dried. The mixture was purified by column chromatography to obtain 4-bromo-2-methoxybenzenesulfonyl chloride (B103-1, 671 mg, 15.8%). 1 H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 8.4 Hz, 1H), 7.30-7.27 (m, 2H), 4.09 (s, 3H).

[0177] Second step: 4-bromo-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-2) 4-Bromo-2-methoxybenzenesulfonyl chloride (B103-1, 200 mg, 0.7 mmol) was dissolved in dichloromethane (8 mL), and 1-methyl-4-(methylamino)piperidine (99 mg, 0.77 mmol) and triethylamine (142 mg, 1.40 mmol) were added in the above reaction system in that order, and the reaction was allowed to proceed at room temperature for 14 hours. The completion of the reaction was detected by TLC. The reaction solution was then dried by rotary evaporation and purified by column chromatography to obtain 4-bromo-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-2, 264 mg, 100%). MS (ESI) m / z: Calculated value 377.05 (M+H + ), actual value 377.40.

[0178] Third step: (3-Methoxy-4-(N-methyl-N-(1-methylpiperidin-4-yl)aminosulfonyl)phenyl)boronic acid (B103-3) 4-Bromo-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-2, 264 mg, 0.70 mmol) and triisopropyl borate (396 mg, 2.10 mmol) were added to tetrahydrofuran (20 mL), cooled to -78°C, and lithium-n-butoxide (0.84 mL, 2.10 mmol, 2.5 M THF solution) was slowly added dropwise. After the addition was completed, the mixture was allowed to return to room temperature and reacted for 14 hours, and the completion of the reaction was detected by LCMS. An appropriate amount of water (1 mL) was added to the system to quench the reaction, and most of the inorganic salts were removed by filtration. After rotary drying, the mixture was used in the next step without any purification. MS (ESI) m / z: Calculated value 343.14 (M+H + ), actual value 343.60.

[0179] Fourth step: 4-(6-bromopyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-4) (3-Methoxy-4-(N-methyl-N-(1-methylpiperidin-4-yl)aminosulfonyl)phenyl)boronic acid (B103-3, crude product, theoretical value 0.70 mmol), 2,6-dibromopyrazine (200 mg, 0.84 mmol), and tetrakis(triphenylphosphine)palladium (40 mg, 0.035 mmol) were placed in 1,4-dioxane / water (4:1, 10 mL) and reacted at 80° C. for 5 hours under nitrogen gas protection, and the reaction completion was monitored by LCMS. The reaction solution was dried by rotary evaporation as it was, and then purified by column chromatography to obtain 4-(6-bromopyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-4, 216 mg, 47.9%). MS (ESI) m / z: Calculated value 455.07 (M+H + ), actual value 454.90.

[0180] Fifth step: 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-5) 4-(6-bromopyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-4, 216 mg, 0.48 mmol), (4-bromothiophen-2-yl)boronic acid (98.5 mg, 0.48 mmol), tetrakis(triphenylphosphine)palladium (27 mg, 0.023 mmol), potassium carbonate (158 mg, 1.14 mmol) were added to 1,4-dioxane / water (4:1, 10 mL) and reacted at 60° C. for 0.5 hours under the protection of nitrogen gas, and the completion of the reaction was monitored by TLC. The reaction mixture was dried by rotary evaporation and then purified by column chromatography to give 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-5, 182 mg, 71.4%). MS (ESI) m / z: calculated 537.06 (M+H), found 536.90.

[0181] Sixth step: 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-6) 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-5, 182 mg, 0.34mmol), cuprous iodide (13 mg, 0.07 mmol), L-proline (16 mg, 0.14 mmol), dimethyl sulfoxide (2 mL) and aqueous ammonia (25%wt, 286 mg, 2.04 mmol) were added in sequence to a sealed tube, sealed at 80°C and reacted for 10 hours, and the completion of the reaction was monitored by LCMS. The reaction mixture was cooled to room temperature, 20 mL of water was added, and the mixture was extracted with ethyl acetate (10 mL×), and the organic phases were combined, washed with saturated ammonium chloride (10 mL×2), dried over anhydrous sodium sulfate, and rotovapped to obtain 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-6, crude product, theoretical value 0.34 mmol), which was used directly in the next step reaction without any purification. MS (ESI) m / z: calculated value 474.16 (M+H), found value 474.10.

[0182] Seventh step: 2-cyclopropyl-N-(5-(6-(3-methoxy-4-(N-methyl-N-(1-methylpiperidin-4-yl)sulfamoyl)phenyl)pyrazin-2-yl)thiophen-3-yl)acetamide (B103) 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide (B103-6, crude product, theoretical value 0.17 mmol) was added to DMF (3 mL), cyclopropylacetic acid (25.4 mg, 0.25 mmol), L-proline (65 mg, 0.34 mmol), HOBT (46 mg, 0.34 mmol) and DIEA (109 mg, 0.84 mmol) were added to the reaction bottle in order, and the reaction was allowed to proceed at room temperature for 14 hours, and the completion of the reaction was detected by LCMS. The reaction solution was diluted with sufficient water, extracted with ethyl acetate (20 mL x 3), the ethyl acetate phase was combined, and the organic phase was washed with saturated ammonium chloride (10 mL x 2), dried over anhydrous sodium sulfate, and rotary evaporated. Purification by column chromatography gave 2-cyclopropyl-N-(5-(6-(3-methoxy-4-(N-methyl-N-(1-methylpiperidin-4-yl)sulfamoyl)phenyl)pyrazin-2-yl)thiophen-3-yl)acetamide (B103, 25 mg, 26.4%). MS (ESI) m / z: calculated 556.20 (M+H + ), actual value 556.00. 1 H NMR (400 MHz, DMSO) δ 10.35 (s, 1H), 9.27 (s, 1H), 9.15 (s, 1H), 8.01-7.86 (m, 4H), 7.75 (t, J = 2.4 Hz, 1H), 4.03 (s, 3H), 3.64-3.57 (m, 1H), 2.85-2.74 (m, 5H), 2.22 (d, J = 7.0 Hz, 2H), 2.12 (s, 3H), 1.89 (t, J = 11.0 Hz, 2H), 1.76-1.66 (m, 2H), 1.36 (d, J = 13.0 Hz, 2H), 1.29-1.20 (m, 1H), 0.55-0.46 (m, 2H), 0.26-0.17 (m, 2H).

[0183] Examples 153-157 (compounds B101-105) were prepared by experimental procedures similar to those of Example 155 above, and compounds B101-105 are summarized in Table 7. [Table 7-1] [Table 7-2] [Table 7-3]

[0184] Example 158 Preparation of 2-cyclopropyl-N-(5-(6-(4-(1-methylpiperidine-4-carbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (E2) [ka]

[0185] First step: 7-bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-1) 2-Amino-5-bromophenol (500 mg, 2.66 mmol), 1,2-dibromoethane (1 g, 5.32 mmol), potassium carbonate (735 mg, 5.32 mmol), and acetonitrile (35 mL) were added to a reaction bottle in that order and reacted at 80° C. for 16 h. Completion of the reaction was monitored by LCMS. The reaction mixture was concentrated, added to water, extracted with ethyl acetate, and the aqueous phase was extracted once more. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was concentrated and purified by column chromatography. 7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-1, 190 mg, 33.4%) was obtained. MS (ESI) m / z: calculated 216.1 (M+H), found 216.10.

[0186] Second step: 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-2) 7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-1, 190 mg, 0.89 mmol), bis(pinacolato)diboron (271 mg, 1.07 mmol), potassium acetate (218 mg, 2.22 mmol), Pd(dppf)2Cl2 (33 mg, 0.05 mmol), and 1,4-dioxane (10 mL) were added to a reaction bottle in that order, and the reaction was carried out at 80°C for 6 h under nitrogen gas protection. Completion of the reaction was monitored by LCMS, and the reaction solution was filtered, the solid was washed with ethyl acetate, and the filtrate was collected and concentrated. The product was purified by column chromatography. 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-2, 243 mg, 100%) was obtained. MS (ESI) m / z: calculated 262.15, (M+H), found 262.10.

[0187] Third step: 7-(6-bromopyrazin-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-3) 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-2, 243 mg, 0.93 mmol), 2,6-dibromopyrazine (266 mg, 1.12 mmol), potassium carbonate (309 mg, 2.24 mmol), Pd(PPh3)4 (54 mg, 0.05 mmol), and 1,4-dioxane:water=4:1 (15 mL) were added to a reaction bottle in that order, and the reaction was carried out at 80° C. for 6 h under the protection of nitrogen gas. The completion of the reaction was monitored by LCMS. The reaction solution was diluted with water, extracted with EA, the aqueous phase was extracted once more, and the organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was concentrated and purified by column chromatography. 7-(6-bromopyrazin-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-3, 120 mg, 44.12%) was obtained. MS (ESI) m / z: calculated 292.00 (M+H), found 293.90.

[0188] Fourth step: 7-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-4) 7-(6-bromopyrazin-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-3, 120 mg, 0.41 mmol), (4-bromothiophen-2-yl)boronic acid (85 mg, 0.41 mmol), potassium carbonate (136 mg, 0.98 mmol), Pd(PPh3)4 (24 mg, 0.02 mmol), and 1,4-dioxane:water=4:1 (10 mL) were added to a reaction bottle in that order, and the reaction was carried out at 60°C for 40 min under the protection of nitrogen gas. The reaction was monitored for completion by LCMS, and the mixture was extracted with EA after adding water, and the aqueous phase was extracted once more. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was concentrated and purified by column chromatography. 7-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-4, 85 mg, 55.19%) was obtained. MS (ESI) m / z: calculated 373.99 (M+H), found 376.00.

[0189] Fifth step: 1-methylpiperidine-4-carbonyl chloride (E2-5) 1-Methylpiperidine-4-carboxylic acid (150 mg, 1.05 mmol) was placed in a bottle, dichloromethane (10 mL) was added, and oxalyl chloride (266 mg, 2.10 mmol) was slowly added dropwise. After completion, N,N-dimethylformamide (0.5 mL) was added dropwise and reacted at room temperature for 3 h. The reaction solution was rotovapped to dryness to obtain 1-methylpiperidine-4-carbonyl chloride (E2-5, 167 mg, 99.82%).

[0190] Sixth step: (7-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)(1-methylpiperidin-4-yl)ketone (E2-6) 7-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (E2-4, 85 mg, 0.23 mmol), 1-methylpiperidine-4-carbonyl chloride (E2-5, 55 mg, 0.34 mmol), and 1,2-dichloroethane (8 mL) were added to a reaction vessel in that order and reacted at 85° C. for 2 h. The reaction was monitored for completion by LCMS. The mixture was diluted with water, extracted with DCM, the aqueous phase was extracted once more, and the organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. Concentration gave the crude product (7-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)(1-methylpiperidin-4-yl)ketone (E2-6, 60 mg, 53.1%). MS (ESI) m / z: calculated 499.07 (M+H), found 501.20.

[0191] Seventh step: (7-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)(1-methylpiperidin-4-yl)ketone (E2-7) (7-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)(1-methylpiperidin-4-yl)ketone (E2-6, 60 mg, 0.12mmol), cuprous iodide (5 mg, 0.03 mmol), L-proline (6 mg, 0.06 mmol), potassium carbonate (25 mg, 0.18 mmol), dimethyl sulfoxide (4 mL), and aqueous ammonia (42 mg, 1.2 mmol) were added in sequence to a sealed tube and reacted at 80°C for 10 h. The reaction was monitored for completion by LCMS. The reaction solution was poured into water, extracted with EA, and the aqueous phase was extracted once more. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was (7-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)(1-methylpiperidin-4-yl)ketone (E2-7, 20 mg, 38.5%). MS (ESI) m / z: calculated 436.17 (M+H), found 436.30.

[0192] Eighth step: 2-cyclopropyl-N-(5-(6-(4-(1-methylpiperidine-4-carbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (E2) 1-Cyclopropylacetic acid (7 mg, 0.07 mmol), EDCI (18 mg, 0.09 mmol), HOBT (12 mg, 0.09 mmol), and N,N-dimethylformamide (5 mL) were placed in a reaction bottle and reacted at room temperature for 5 min. Then, N,N-diisopropylethylamine (30 mg, 0.23 mmol), (7-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)(1-methylpiperidin-4-yl)ketone (E2-7, 20 mg, 0.05 mmol) were added and reacted at room temperature overnight. The reaction was monitored for completion by MS, charged with water, extracted with EA, the aqueous phase was extracted once more, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated and purified by column chromatography to give 2-cyclopropyl-N-(5-(6-(4-(1-methylpiperidine-4-carbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (E2, 5.18 mg, 21.7%). MS (ESI) m / z: calculated value 518.21 (M+H), measured value 518.50;1H NMR (400 MHz, DMSO) δ 10.33 (s, 1H), 9.12 (s, 1H), 9.02 (s, 1H), 7.89 (d, J = 1.4 Hz, 1H), 7.79-7.71 (m, 3H), 4.38-4.31 (m, 2H), 4.01-3.93 (m, 2H), 2.92-2.79 (m, 3H), 2.22 (d, J = 7.1 Hz, 2H), 2.20 (s, 2H), 2.12 (d, J = 7.0 Hz, 1H), 2.02-1.92 (m, 2H), 1.82-1.65 (m, 4H), 1.11-1.05 (m, 1H), 0.52-0.43 (m, 2H), 0.23-0.19 (m, 1H), 0.14-0.08 (m, 1H).

[0193] Example 159 is the preparation of compound E1 by the experimental procedure similar to that of Example 158 above, see Table 8. [Table 8]

[0194] Example 160 Preparation of 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (F1) [ka]

[0195] First step: 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl-2-methoxybenzoic acid methyl ester (F1-1) 4-(6-(4-Bromothiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid methyl ester (B4-3, 200 mg, 0.49 mmol), cuprous iodide (19 mg, 0.1 mmol), L-proline (23 mg, 0.2 mmol), and potassium carbonate (102 mg, 0.74 mmol) were placed in dimethyl sulfoxide (4 mL), and aqueous ammonia (1.0 mL) was added. The tube was sealed, heated to 80 °C, and stirred for 8 h. After the completion of the reaction was confirmed by TLC, it was poured into water and extracted with ethyl acetate. The organic phase was washed three times with deionized water, dried over anhydrous sodium sulfate, and the ethyl acetate was concentrated to give 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl-2-methoxybenzoic acid methyl ester (F1-1, 150 mg, 89%). MS (ESI) m / z: calculated 342.08 (M+H), found 342.1.

[0196] Second step: 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid methyl ester (F1-2) 4-(6-(4-aminothiophen-2-yl)pyrazin-2-yl-2-methoxybenzoic acid methyl ester (F1-1, 148 mg, 0.43 mmol) was added to dichloromethane (10 mL), triethylamine (53 mg, 0.52 mmol) and chloroformic acid phenyl ester (75 mg, 0.48 mmol) were added, and the mixture was stirred at room temperature for 4 h. The reaction was monitored for completion by LCMS. The reaction mixture was washed three times with water, and the organic phase was dried over anhydrous sodium sulfate and concentrated. The product and cyclobutylamine (34 mg, 0.48 mmol) were added to N,N-dimethylformamide (8 mL), N,N-diisopropylethylamine (181 mg, 1.4 mmol) were added, and the mixture was stirred at room temperature for 4 h. The mixture was stirred for 1 h. The reaction was monitored for completion by LCMS. The reaction was poured into water, extracted with ethyl acetate, the organic phase was washed three times with deionized water, dried over anhydrous sodium sulfate, and the ethyl acetate was concentrated. Purification by column chromatography gave 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid methyl ester (F1-2, 75 mg, 39.5%). MS (ESI) m / z: calculated 439.14 (M+H), found 349.3.

[0197] Third step: 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid (F1-3) 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid methyl ester (F1-2, 75 mg, 0.17 mmol) was placed in a mixture of tetrahydrofuran and water (8 mL, 2 mL) and lithium hydroxide (29 mg, 0.69 mmol) was added and stirred at room temperature for 16 h. Completion of the reaction was monitored by LCMS. The reaction was adjusted to weak acidity with 2M hydrochloric acid, extracted three times with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid (F1-3, 40 mg, 55.3%) was obtained. MS (ESI) m / z: calculated 425.12, (M+H), found 452.2.

[0198] Fourth step: 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (F1-4) 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid (F1-3, 40 mg, 0.094 mmol) and 1-methyl-4-(methylamino)piperidine (15 mg, 0.12 mmol), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (72 mg, 0.19 mmol) were added to dichloromethane, and N,N-diisopropylethylamine (49 mg, 0.38 mmol) was added and stirred at room temperature for 1 h. Completion of the reaction was monitored by TLC. The reaction solution was washed with water, and the organic phase was dried over anhydrous sodium sulfate and concentrated. Purification by column chromatography gave 4-(6-(4-(3-cyclobutylureido)thiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (F1, 25 mg, 49.8%). MS (ESI) m / z: calculated 535.24, (M+H), found 535.4. 1H NMR (400 MHz, DMSO) δ 9.21 (d, J = 10.7 Hz, 1H), 9.10 (d, J = 2.6 Hz, 1H), 8.69 (s, 1H), 7.84 (d, J = 8.2 Hz, 3H), 7.40 (s, 1H), 7.34 (t, J = 7.3 Hz, 1H), 6.51 (d, J = 7.8 Hz, 1H), 4.21-4.07 (m, 1H), 3.93 (d, J = 2.7 Hz, 3H), 3.16 (s, 1H), 2.95-2.61 (m, 6H), 2.22-2.17 (m, 2H), 2.09-1.94 (m, 4H), 1.92-1.75 (m, 4H), 1.69-1.54 (m, 4H).

[0199] Example 161 Preparation of (S)-4-(6-(4-(4-amino-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl)-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (G1) [ka]

[0200] First step: 2-Methoxy-4-(6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaboronic acid-2-yl)thiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (G1-1) 4-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid methyl ester (B4-3, 200 mg, 0.49 mmol), bis(pinacolato)diboron (150 mg, 0.59 mmol), Pd(dppf)2Cl2 (18 mg, 0.02 mmol), potassium acetate (121 mg, 1.23 mmol), and 1,4-dioxane (10 mL) were added to a reaction bottle in that order, and the reaction was carried out at 80° C. for 14 h under nitrogen gas protection. The completion of the reaction was monitored by MS, and the reaction solution was filtered. The solid was washed with ethyl acetate and the filtrate was concentrated and purified by column chromatography to give 2-methoxy-4-(6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaboronic acid-2-yl)thiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (G1-1, 197 mg, 89.8%). MS (ESI) m / z: calculated 453.16 (M+H), found 453.50.

[0201] Second step: (5-(6-(3-methoxy-4-(methoxycarbonyl)phenyl)pyrazin-2-yl)thiophen-3-yl)boronic acid (G1-2) 2-Methoxy-4-(6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaboronic acid-2-yl)thiophen-2-yl)pyrazin-2-yl)benzoic acid methyl ester (G1-1, 197 mg, 0.44 mmol), sodium periodate (189 mg, 0.88 mmol), sodium acetate (171 mg, 2.21 mmol), and tetrahydrofuran:water=3:1 (10 mL) were added to a reaction bottle in that order and reacted at room temperature for 14 h. Completion of the reaction was monitored by LCMS, and the reaction solution was filtered, and the solid was collected, washed with water, and dried by heating to give yellow (5-(6-(3-methoxy-4-(methoxycarbonyl)phenyl)pyrazin-2-yl)thiophen-3-yl)boronic acid (G1-2, 110 mg, 67.6%). MS (ESI) m / z: calculated 371.08(M+H), found 371.30.

[0202] Third step: 4-(6-(4-hydroxythiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid methyl ester (G1-3) (5-(6-(3-Methoxy-4-(methoxycarbonyl)phenyl)pyrazin-2-yl)thiophen-3-yl)boronic acid (G1-2, 110mg, 0.30mmol) was placed in a bottle, tetrahydrofuran (10mL) was added, and the mixture was allowed to react in an ice bath. Water peroxide (35%, 230mg, 2.37mmol) was slowly added dropwise, followed by 2mol / L hydroxide solution (5mg). After the addition was complete, the ice bath was removed, and the mixture was allowed to react at room temperature for 14h. The completion of the reaction was monitored by LCMS. The reaction solution was filtered, and the solid was collected, washed with water, and dried by heating. 4-(6-(4-hydroxythiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid methyl ester (G1-3, 54mg, 48.9%) was obtained. MS (ESI) m / z: calculated value 342.07(M+H), found value 343.30.

[0203] Fourth step: (R)-4-((t-butoxycarbonyl)amino)-3-methylmethanesulfonic acid butyl ester (G1-4) (R)-(4-hydroxy-2-methylbutyl)carbamate (100 mg, 0.49 mmol) was placed in a bottle, dichloromethane (10 mL) was added, and the mixture was allowed to react in an ice bath. Triethylamine (149 mg, 1.47 mmol) was then added, followed by slow dripping of methanesulfonyl chloride (68 mg, 0.59 mmol). After completion of the dripping, the ice bath was removed, and the mixture was allowed to react at room temperature for 30 min. Completion of the reaction was monitored by LCMS. The reaction was quenched by adding water, extracted with dichloromethane, the aqueous phase was extracted once more, the organic phase was combined, washed with saturated saline, and dried over anhydrous sodium sulfate. The mixture was concentrated to obtain the crude product (R)-4-((t-butoxycarbonyl)amino)-3-methylmethanesulfonic acid butyl ester (G1-4, 131 mg, 94.93%). MS (ESI) m / z: calculated 282.13, found 282.40.

[0204] Fifth step: (S)-4-(6-(4-(4-(t-butoxycarbonyl)amino)-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl-2-methoxybenzoic acid methyl ester (G1-5) 4-(6-(4-hydroxythiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid methyl ester (G1-3, 54 mg, 0.16 mmol), (R)-4-((t-butoxycarbonyl)amino)-3-methylmethanesulfonic acid butyl ester (G1-4, 53 mg, 0.19 mmol), cesium carbonate (103 mg, 0.32 mmol), and N,N-dimethylformamide (10 mL) were placed in a bottle in that order and reacted at 100 °C for 14 h. Completion of the reaction was monitored by MS. The reaction solution was added with water and extracted with ethyl acetate, and the aqueous phase was extracted once more. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. Concentration and purification by column chromatography gave (S)-4-(6-(4-(4-(t-butoxycarbonyl)amino)-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl-2-methoxybenzoic acid methyl ester (G1-5, 40 mg, 48.2%). MS (ESI) m / z: calculated 528.21 (M+H), found 528.40.

[0205] Sixth step: (S)-4-(6-(4-(4-((t-butoxycarbonyl)amino)-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid (A1-06) (S)-4-(6-(4-(4-(t-butoxycarbonyl)amino)-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl-2-methoxybenzoic acid methyl ester (G1-5, 40 mg, 0.08 mmol), lithium hydroxide (13 mg, 0.31 mmol), and tetrahydrofuran:water=4:1 (10 mL) were added to a reaction bottle in that order and reacted at room temperature for 14 h. Completion of the reaction was monitored by MS. The reaction mixture was adjusted to pH 6 with citric acid, water was added, extracted with ethyl acetate, the aqueous phase was extracted once more, the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated to give crude (S)-4-(6-(4-(4-((t-butoxycarbonyl)amino)-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid (G1-6, 45 mg). MS (ESI) m / z: calculated 514.19 (M+H), found 514.40.

[0206] Seventh step: (S)-(4-(5-(6-(3-methoxy-4-(methyl(1-methylpiperidin-4-ylcarbamoyl)phenyl)pyrazin-2-yl)thiophen-3-yloxy)-2-methylbutyl)carbamic acid t-butyl ester (G1-7) (S)-4-(6-(4-(4-((t-butoxycarbonyl)amino)-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl)-2-methoxybenzoic acid (G1-6, 45 mg, 0.09 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (67 mg, 0.18 mmol), and dichloromethane (10 mL) were added and reacted at room temperature for 5 min, and then 1-methyl-4-(methylamino)piperidine (14 mg, 0.11 mmol) and N,N-diisopropylethylamine (45 mg, 0.35 mmol) were added and reacted at room temperature for 2 h. The reaction was monitored for completion by LCMS, charged with water, extracted with DCM, the aqueous phase was extracted once more, and the organic phases were combined, washed with brine, and dried over anhydrous sodium sulfate. It was concentrated and purified by column chromatography to give (S)-(4-(5-(6-(3-methoxy-4-(methyl(1-methylpiperidin-4-ylcarbamoyl)phenyl)pyrazin-2-yl)thiophen-3-yloxy)-2-methylbutyl)carbamic acid tert-butyl ester (G1-7, 21 mg, 38.2%). MS (ESI) m / z: calculated 624.31, (M+H), found 624.50.

[0207] Eighth step: (S)-4-(6-(4-(4-amino-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl]-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (G1) (S)-(4-(5-(6-(3-methoxy-4-(methyl(1-methylpiperidin-4-ylcarbamoyl)phenyl)pyrazin-2-yl)thiophen-3-yloxy)-2-methylbutyl)carbamic acid t-butyl ester (G1-7, 21 mg, 0.03 mmol) was added to a solution of hydrochloric acid in ethyl acetate (3 mol / L, 3 mL) and ethyl acetate (1 mL), and the mixture was reacted at room temperature for 30 min. The reaction was monitored for completion by LCMS, and the reaction solution was dried by rotation. (S)-4-(6-(4-(4-amino-3-methylbutoxy)thiophen-2-yl)pyrazin-2-yl]-2-methoxy-N-methyl-N-(1-methylpiperidin-4-yl)benzamide hydrochloride salt (G1, 12 mg, 66.67%) was obtained as a yellow solid product. MS (ESI) m / z: calculated value 524.26 (M+H), found 524.50; 1 H NMR (400 MHz, DMSO) δ 9.21 (dd, J = 15.2, 7.4 Hz, 2H), 8.10 (s, 3H), 7.95-7.74 (m, 3H), 7.46-7.33 (m, 1H), 6.96-6.88 (m, 1H), 4.12-4.06 (m, 1H), 3.94 (s, 3H), 3.65-3.53 (m, 2H), 3.47 (d, J = 11.2 Hz, 1H), 3.41-3.23 (m, 2H), 3.23-3.07 (m, 2H), 2.91-2.81 (m, 3H), 2.74-2.67 (m, 3H), 2.59 (d, J = 4.6 Hz, 2H), 2.38-2.17 (m, 2H), 2.08-1.96 (m, 1H), 1.95-1.87 (m, 1H), 1.80 (t, J = 12.1 Hz, 1H), 1.70-1.56 (m, 2H), 1.02 (d, J = 6.7 Hz, 3H).

[0208] Examples 162-164 (compounds A46-A48) were prepared by experimental procedures similar to those of Example 35 above, and compounds A46-A48 are summarized in Table 9. [Table 9]

[0209] Example 166 Preparation of 2-cyclobutyl-N-(5-(6-(2-(1-methylpiperidin-4-yl)methyl)-2H-indazol-6-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (A50) [ka]

[0210] First step: t-butyl 4-(6-bromo-2H-indazol-2-yl)methyl)piperidine-1-carboxylate (A50-1) 6-Bromo-1H-indazole (600 mg, 3.04 mmol), 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester (1.0 g, 3.6 mmol), and cesium carbonate (1.98 g, 6.08 mmol) were added to N,N-dimethylformamide (10 ml) and heated to 60° C. and stirred for 3 h. After completion of the reaction was confirmed by LCMS and TLC, the mixture was poured into water and extracted with ethyl acetate. The organic phase was washed three times with water, dried over anhydrous sodium sulfate, and the ethyl acetate was concentrated. The product was purified by column chromatography to give 4-(6-bromo-2H-indazol-2-yl)methyl)piperidine-1-carboxylate tert-butyl ester (A50-1, 630 mg, 52.3%). MS (ESI) m / z: calculated 394.11 (M+H), found 338.2.

[0211] Second step: 4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazol-2-ylmethyl)piperidine-1-carboxylic acid t-butyl ester (A50-2) 4-(6-bromo-2H-indazol-2-yl)methyl)piperidine-1-carboxylic acid t-butyl ester (A50-1, 630 mg, 1.59 mmol), bis(pinacolato)diboron (487 mg, 1.90 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (58 mg, 0.08 mmol), potassium acetate (392 mg, 3.98 mmol) were placed in dioxane (10 mL) and heated to 80° C. under nitrogen gas protection and stirred for 14 h. After completion of the reaction was confirmed by LCMS and TLC, the crude product was directly used in the next step. 4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazol-2-ylmethyl)piperidine-1-carboxylic acid tert-butyl ester (A50-2, 705 mg crude, theory 1.59 mmol) was obtained. MS (ESI) m / z: calculated 442.28 (M+H), found 442.5.

[0212] Third step: 4-((6-(6-bromopyrazin-2-yl)-2H-indazol-2-yl)methyl)piperidine-1-carboxylic acid t-butyl ester (A50-3) 4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazol-2-ylmethyl)piperidine-1-carboxylic acid t-butyl ester (A50-2, 705 mg crude product, theoretical value 1.59 mmol), 2,6-dibromopyrazine (456 mg, 1.90 mmol), tetrakis(triphenylphosphine)palladium (92 mg, 0.08 mmol), and potassium carbonate (530 mg, 3.80 mmol) were placed in a mixed solvent of dioxane / water (12 mL / 3 mL) and heated to 80° C. under the protection of nitrogen gas to obtain 8-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazol-2-ylmethyl)piperidine-1-carboxylic acid t-butyl ester (A50-2, 705 mg crude product, theoretical value 1.59 mmol), 2,6-dibromopyrazine (456 mg, 1.90 mmol), tetrakis(triphenylphosphine)palladium (92 mg, 0.08 mmol), and potassium carbonate (530 mg, 3.80 mmol) in a mixed solvent of dioxane / water (12 mL / 3 mL). The mixture was stirred for 1 h. After completion of the reaction was confirmed by LCMS and TLC, it was poured into water and extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, and the ethyl acetate was concentrated. Purification by column chromatography gave 4-((6-(6-bromopyrazin-2-yl)-2H-indazol-2-yl)methyl)piperidine-1-carboxylic acid tert-butyl ester (A50-3, 280 mg, 37.1%). MS (ESI) m / z: calculated 472.13 (M+H), found 374.2.

[0213] Fourth step: 4-(6-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid t-butyl ester (A50-4) 4-((6-(6-bromopyrazin-2-yl)-2H-indazol-2-yl)methyl)piperidine-1-carboxylic acid t-butyl ester (A50-3, 280 mg, 0.59 mmol) and (4-bromothiophen-2-yl)boronic acid (122 mg, 0.59 mmol), tetrakis(triphenylphosphine)palladium (35 mg, 0.03 mmol), potassium carbonate (197 mg, 1.44 mmol) were added to a mixed solvent of dioxane / water (12 mL / 3 mL), heated to 60° C. under nitrogen gas protection, and stirred for 0.5 h. After confirming the completion of the reaction by MS and TLC, it was poured into water and extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, and the ethyl acetate was concentrated. Purification by column chromatography gave 4-(6-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid tert-butyl ester (A50-4, 240 mg, 83.0%). MS (ESI) m / z: calculated 554.11 (M+H), found 456.2.

[0214] Fifth step: 4-(6-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid t-butyl ester (A50-5) 4-(6-(6-(4-bromothiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid t-butyl ester (A50-4, 240 mg, 0.49 mmol) and cuprous iodide (16 mg, 0.10 mmol), L-proline (19 mg, 0.20 mmol), potassium carbonate (85 mg, 1.18 mmol) were added to dimethyl sulfoxide (4 mL), and aqueous ammonia (1 mL) was added. The tube was sealed and heated to 80 °C and stirred for 8 h. After confirming the completion of the reaction by TLC, it was poured into water and extracted with ethyl acetate, the organic phase was washed with water three times, dried over anhydrous sodium sulfate, the ethyl acetate was concentrated, and the crude product was directly used in the next step. 4-(6-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid tert-butyl ester (A50-5, 220 mg crude, 0.49 mmol theory) was obtained. MS (ESI) m / z: calculated 491.22 (M+H), found 491.6.

[0215] Sixth step: 4-(6-(6-(4-(2-cyclobutylacetamido)thiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid t-butyl ester (A50-6) 4-(6-(6-(4-aminothiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid t-butyl ester (A50-5, 220 mg crude product, 0.49 mmol theoretical value) and 2-cyclobutylacetic acid (62 mg, 0.54 mmol), 1-hydroxybenzotriazole (122 mg, 0.90 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (172 mg, 0.90 mmol) were placed in dichloromethane (12 mL), N,N-diisopropylethylamine (232 mg, 1.80 mmol) was added, and the mixture was stirred at room temperature for 4 h. After the completion of the reaction was confirmed by LCMS and TLC, it was poured into water and extracted with ethyl acetate, the organic phase was washed with water three times, dried over anhydrous sodium sulfate, and the ethyl acetate was concentrated. Purification by column chromatography gave 4-(6-(6-(4-(2-cyclobutylacetamido)thiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid tert-butyl ester (A50-6, 70 mg, 20.4%). MS (ESI) m / z: calculated 586.27 (M+H), found 487.6.

[0216] Seventh step: 2-cyclobutyl-N-(5-(6-(2-(2-(piperidin-4-ylmethyl)-2H-indazol-6-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (A50-7) 4-(6-(6-(4-(2-cyclobutylacetamido)thiophen-2-yl)pyrazin-2-yl)-2H-indazol-2-yl))methylpiperidine-1-carboxylic acid tert-butyl ester (A50-6, 70 mg, 0.1 mmol) was dissolved in 2 mL of ethyl acetate and added with 4 mL of 3M hydrogen chloride in ethyl acetate and stirred at room temperature for 10 h. The reaction was monitored for completion by TLC. The solvent was removed by rotary evaporation and the crude product was directly used in the next step. 2-Cyclobutyl-N-(5-(6-(2-(2-(piperidin-4-ylmethyl)-2H-indazol-6-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (A50-7, 90 mg crude, 0.1 mmol theory). MS (ESI) m / z: calculated 486.22 (M+H), found 487.5.

[0217] Eighth step: 2-cyclobutyl-N-(5-(6-(2-(1-methylpiperidin-4-yl)methyl)-2H-indazol-6-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (A50) 2-Cyclobutyl-N-(5-(6-(2-(2-(piperidin-4-ylmethyl)-2H-indazol-6-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (A50-7, 90 mg crude product, 0.1 mmol (theoretical value)), formaldehyde (55 mg, 1.90 mmol), and acetic acid (34.2 mg, 0.57 mmol) were added to methanol (12 mL) and stirred at room temperature for 0.5 h. Then, sodium triacetoxyborohydride (196 mg, 0.93 mmol) was added and the mixture was stirred at room temperature for 14 h. The mixture was stirred for 1 h. After completion of the reaction by LCMS and TLC, the solvent was removed by rotary evaporation. Extraction with water and ethyl acetate was carried out, the organic phase was dried over anhydrous sodium sulfate, and the ethyl acetate was concentrated. Purification by column chromatography gave 2-cyclobutyl-N-(5-(6-(2-(1-methylpiperidin-4-yl)methyl)-2H-indazol-6-yl)pyrazin-2-yl)thiophen-3-yl)acetamide (A50, 20 mg, 39.9%). MS (ESI) m / z: calculated 501.24 (M+H), found 501.40. 1 H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.23 (s, 1H), 9.03 (s, 1H), 8.50 (s, 1H), 8.45 (s, 1H), 7.90 (dd, J = 5.0, 1.1 Hz, 3H), 7.71 (d, J = 1.2 Hz, 1H), 4.37 (d, J = 7.2 Hz, 2H), 2.79-2.69 (m, 2H), 2.69-2.65 (m, 1H), 2.44 (d, J = 7.6 Hz, 2H), 2.13 (s, 2H), 2.10-2.05 (m, 1H), 2.02-1.93 (m, 1H), 1.91-1.82 (m, 2H), 1.80 (s, 3H), 1.78-1.69 (m, 2H), 1.45 (d, J = 10.8 Hz, 2H), 1.35-1.26 (m, 3H).

[0218] Examples 165-168 (compounds A49-A52) were prepared by experimental procedures similar to those of Example A50 above, and compounds A49-A52 are summarized in Table 10. [Table 10-1] [Table 10-2]

[0219] Example 1 How to test for Drak2 activity The activity of Drak2 was detected using Promega's ADP-Glo ​​Kinase Detection Kit. The reaction was carried out in a 384-white shallow well plate, with a total volume of 5 μL. Specifically, it contained 1 μL of the test compound (2% DMSO), 2 μL of Drak2 and 2 μL of ATP, and the reaction buffer was 50 mM Na3PO4, 0.02% NaN 3, After incubation for 2 hours at room temperature in 0.1 mM Na3VO4, 5 mM MgCl2, 0.01% (w / v) BSA, 50 mM HEPES pH7.0 (the above reaction buffer system is used to dilute Drak2 and ATP, and the above concentrations are the concentrations in the total volume of the reaction system of 5μL), 5μL of ADP-Glo ​​stop buffer (reagent in the kit) was added to stop the kinase reaction and consume the remaining ATP, and after reaction for 1 hour, kinase detection reagent (reagent in the kit) was added and incubated for half an hour to convert ADP to ATP, and at the same time, newly synthesized ATP was detected by reacting with coupled luciferase / fluorescein (reagent in the kit), and the value was read with Envision multi-label plate reader to detect the effect of the test compound on Drak2 kinase activity. The parameter of Envision was Aperure, specifically, 384 plate US Luminescence aperture-In. The reactions included background wells without Drak2 and total Drak2 enzyme activity wells without any compound.

[0220] IC of compounds that inhibit Drak2 kinase activity 50 Values ​​were calculated using Graphpad Prism 7.00 software by the formula: Y=100 / (1+10^((LogIC50-X)*HillSlope)). Activity range: A: <10 nM; B: 10 -100 nM; C: 101-1000 nM, D: 1001-10000 nM; E: >10000 nM. [Table 11-1] [Table 11-2] [Table 11-3] [Table 11-4] [Table 11-5]

[0221] The activity data in the above table show that the compounds of the present invention have Drak2 kinase inhibitory activity.

[0222] All documents related to the present invention are incorporated herein by reference as if each document were incorporated individually. After reading the above content of the present invention, it will be understood that those skilled in the art can make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.

Claims

1. A compound of formula I or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof. 【Chemistry 1】 (where: X 1 is N or CR m1 Selected from. X 2 is N or CR m2 Selected from. X 3 is N or CR m3 Selected from. X 5 is N or CR' m3 Selected from. L is a bond, —O—, —S, or —NR m4 -, -C(O)- or -C(O)NR m4 -Selected from. Ring A and ring B are each independently selected from a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, and a 5-12 membered heteroaryl group, wherein the C3-C12 cycloalkyl group, the 3-12 membered heterocyclic group, the C6-C10 aryl group, and the 5-12 membered heteroaryl group are optionally substituted with 1-3 R. Each R m are independently H, D, a halogen atom, a cyano group, a hydroxyl group, a carboxyl group, -S(O) t R m5 , -C(O)R m5 , -C(O)OR m5 , -C(O)NR m6 R m7 , -S(O) t N.R. m6 R m7 , -C(O)NR m8 S (O) t N.R. m6 R m7 , -(CH 2 ) q S (O) t R m5 , -(CH 2 ) q C(O)R m5 , -(CH 2 ) q C(O)OR m5 , -(CH 2 ) q C(O)NR m6 R m7 , -(CH 2 ) q (CH 2 ) q S (O) t N.R. m6 R m7 , -C(O)NR m8 S (O) t N.R. m6 R m7 , -(CH 2 ) q R m9 , -C1-C6 alkyl group, -C1-C6 alkoxy group, -C1-C6 alkylamine group, C3-C12 cycloalkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group is optionally substituted by 1-3 R, Alternatively, two R on adjacent ring atoms m together with the ring atoms adjacent thereto form a C3-C12 cycloalkyl group or a 3-12 membered heterocyclic group, wherein said C3-C12 cycloalkyl group or the 3-12 membered heterocyclic group is optionally substituted with 1-3 R. R n is H, a C1-C15 alkyl group, a C2-C15 alkenyl group, a C2-C15 alkynyl group, C(O)R p where R p NH 2 , a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C2-C15 alkenyl group, a C2-C15 alkynyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group or a 5-12 membered heteroaryl group, wherein said C1-C15 alkyl group, C1-C15 alkoxy group, C1-C15 alkylamine group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group or a 5-12 membered heteroaryl group is optionally substituted by 1-3 R. R m1 , R m2 , R m3 and R' m3 are each independently H, a cyano group, a halogen, or C(O)NH 2 , carboxy group, S(O) 2 N.H. 2 , C(O)OC1-C6 alkyl group or S(O) 2 It is selected from C1-C6 alkyl groups. R m4 is selected from H or a C1-C6 alkyl group. R m5 is selected from a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein said C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group is optionally substituted by 1-3 R. R m6 , R m7 , R m8 and R m9 are each independently selected from H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group; or R m6 and R m7 together with the N atom adjacent thereto, constitute a 3-12 membered heterocyclic group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 R. (CH 2 ) q H in is optionally substituted with R. R is H, D, halogen, cyano group, hydroxy group, carboxy group, NH 2 , oxo group (=O), C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group, S(O) 2 C1-C6 alkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, wherein said C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally selected from halogen, cyano group, hydroxy group, carboxy group, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group and S(O) 2 It is substituted with 1 to 3 groups selected from the group consisting of C1-C6 alkyl groups. t is 0, 1 or 2. q is 1, 2, 3, 4, 5 or 6. n is 1, 2, 3, 4, 5 or 6.

2. 2. The compound of claim 1, characterized in that it has a structure represented by Formula II, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof. 【Chemistry 2】 (Here, X 1 , X 2 , X 3 , X 5 , ring A, ring B, R m , R p and n are defined as in claim 1. Specially, X 1 , X 2 , X 3 , X 5 , ring A, ring B, R m is defined as in claim 8, n is defined as in claim 1, 【Chemistry 3】 The definition of R in claim 8 n is the same as: More specially, 【Chemistry 4】 The definition of is as set forth in claim 8.

3. 2. The compound of claim 1, characterized in that it has a structure represented by Formula III: or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof. 【Chemistry 5】 (Here, X 4 is N or CR m10 where R m10 is selected from H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, or R m6 and R m7 form a 3-12 membered heterocyclic group together with the N atom adjacent thereto, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 R. R' is H, D, a halogen, a cyano group, a hydroxyl group, a carboxyl group, NH 2 , a C1-C6 alkyl group, a C1-C6 alkoxy group, and a C1-C6 alkylamine group, and is preferably H. R, X 1 , X 2 , X 3 , X 5 , ring A, R m , R p and n are defined as in claim 1. Specially, X 1 , X 2 , X 3 , X 5 , ring A, R m is defined as in claim 8, n is defined as in claim 1, 【Chemistry 6】 The definition of R in claim 8 n is the same as: More specially, 【Chemistry 7】 The definition of is as set forth in claim 8.

4. 4. The compound of any one of claims 1 to 3, characterized in that it has a structure represented by formula IV, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof. 【Chemistry 8】 (where: R 1 , R 2 , R 3 , R 4 , R 5 are each independently H, D, a halogen atom, a cyano group, a hydroxyl group, a carboxyl group, -S(O) t R m5 , -C(O)R m5 , -C(O)OR m5 , -C(O)NR m6 R m7 , -S(O) t N.R. m6 R m7 , -C(O)NR m8 S (O) t N.R. m6 R m7 , -(CH 2 ) q S (O) t R m5 , -(CH 2 ) q C(O)R m5 , -(CH 2 ) q C(O)OR m5 , -(CH 2 ) q C(O)NR m6 R m7 , -(CH 2 ) q (CH 2 ) q S (O) t N.R. m6 R m7 , -C(O)NR m8 S (O) t N.R. m6 R m7 , -(CH 2 ) q R m9 , -C1-C6 alkyl group, -C1-C6 alkoxy group, -C1-C6 alkylamine group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted by 1-3 R, Or, R 1 and R 2 , or R 2 and R 3 , or R 3 and R 4 , or R 4 and R 5 form a 5-6 membered heterocyclic group together with the C atom adjacent thereto, wherein said 5-6 membered heterocyclic group is optionally substituted with 1-3 R. R' is H, D, a halogen, a cyano group, a hydroxyl group, a carboxyl group, NH 2 , a C1-C6 alkyl group, a C1-C6 alkoxy group, and a C1-C6 alkylamine group, and is preferably H. t, q, R, R m5 , R m6 , R m7 , R m8 , R m9 , X 1 , X 2 , X 3 , X 5 and R p are defined as in claim 1. Specially, X 1 , X 2 , X 3 , X 5 The definition of R is as set forth in claim 8. 1 , R 2 , R 3 , R 4 , R 5 The definition of R in claim 8 m Similarly, 【Chemistry 9】 The definition of R in claim 8 n is the same as: More specially, 【Chemistry 10】 The definition of is as set forth in claim 8.

5. The compound according to any one of claims 1 to 4, characterized in that it has a structure represented by formula A, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof. 【Chemistry 11】 (where: R 6 is H, D, halogen, cyano group, hydroxyl group, carboxyl group, NH 2 , a C1-C6 alkyl group, a C1-C6 alkoxy group, and a C1-C6 alkylamine group, and is preferably H. R 7 is selected from a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C15 alkyl group, the C1-C15 alkoxy group, the C1-C15 alkylamine group, the C3-C12 cycloalkyl group, the 3-12 membered heterocyclic group, the C6-C10 aryl group, or the 5-12 membered heteroaryl group is optionally selected from D, a halogen, a cyano group, a hydroxy group, a carboxy group, NH 2 , oxo group (=O), C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group, S(O) 2 It is substituted with 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a C3-C12 cycloalkyl group, a 3- to 12-membered heterocyclic group, a C6-C10 aryl group, or a 5- to 12-membered heteroaryl group. R 1 , R 2 , R 3 , R 4 and R 5 is defined as in claim 4. In particular, R 1 , R 2 , R 3 , R 4 , R 5 The definition of R in claim 8 m Similarly, 【Chemistry 12】 The definition of R in claim 8 n (Similar to.)

6. The compound according to any one of claims 1 to 4, characterized in that it has a structure represented by formula B, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof. 【Chemistry 13】 (where: R 7 is selected from a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C15 alkyl group, the C1-C15 alkoxy group, the C1-C15 alkylamine group, the C3-C12 cycloalkyl group, the 3-12 membered heterocyclic group, the C6-C10 aryl group, or the 5-12 membered heteroaryl group is optionally selected from D, a halogen, a cyano group, a hydroxy group, a carboxy group, NH 2 , oxo group (=O), C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group, S(O) 2 It is substituted with 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group. R 8 and R 9 are each independently H, S(O) 2 N.R. 11 R 12 , a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group or a 5-12 membered heteroaryl group, or R 8 and R 9 form a 3-12 membered heterocyclic group (preferably a 5-6 membered heterocyclic group) together with the N atom adjacent thereto, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, 5-6 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C(O)OC1-C6 alkyl group, an S(O) 2 It is substituted by 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a C3-C12 cycloalkyl group, a C1-C6 alkyl C3-C12 cycloalkyl group, a 3- to 12-membered heterocyclic group, a C1-C6 alkyl 3- to 12-membered heterocyclic group, a C6-C10 aryl group, or a 5- to 12-membered heteroaryl group. R 11 and R 12 are each independently selected from H, a C1-6 alkyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group. In particular, X 1 , X 2 is defined as in claim 8, 【Chemistry 14】 The definition of R in claim 8 n Similarly, 【Chemistry 15】 teeth, 【Chemistry 16】 It is.)

7. The compound according to any one of claims 1 to 4, characterized in that it has a structure represented by formula C, or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug, or solvate thereof. 【Chemistry 17】 (where: R 10 is H, a cyano group, CONH 2 Selected from. R 7 is selected from a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein the C1-C15 alkyl group, the C1-C15 alkoxy group, the C1-C15 alkylamine group, the C3-C12 cycloalkyl group, the 3-12 membered heterocyclic group, the C6-C10 aryl group, or the 5-12 membered heteroaryl group is optionally selected from D, a halogen, a cyano group, a hydroxy group, a carboxy group, NH 2 , oxo group (=O), C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group, S(O) 2 It is substituted with 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group. In particular, 【Chemistry 18】 The definition of R in claim 8 n (Similar to.)

8. The compound according to claim 1 or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof, characterized in that the compound satisfies one or more of the following conditions: (1) X 1 is N or CH; (2) X 2 is N or CH; (3) X 3 is N, CC(=O)NH 2 or C-CN; (4) X 5 is N or CH; (5) L is a bond or NH; (6) Ring A is a C6-C10 aryl group or a 3-12 membered heterocyclic group, wherein the 3-12 membered heterocyclic group is preferably a 5-7 membered heterocyclic group, more preferably a 6 membered heterocyclic group, and preferably, Ring A is a benzene ring. 【Chemistry 19】 The definition of the substituent in ring A is R in claim 1. m is the same as: (7) Ring B is a 5-12 membered heteroaryl group or a C3-C12 cycloalkyl group, preferably a 5 membered heteroaryl group or a 6 membered cycloalkyl group, and preferably Ring B is 【Chemistry 20】 The definition of the substituent in ring B is the same as R in claim 1; (8) R m is a methoxy group, a fluorine group, a chlorine group, a cyano group, a hydroxy group, a carboxy group, a carboxamide group, 【Chemistry 21】 is; (9) R n teeth, 【Chemical 22】 Acetyl group, isobutyryl group, 【Chemistry 23】 a cyclopropylcarbonyl group, a cyclobutylcarbonyl group, a cyclopentylcarbonyl group, a cyclohexylcarbonyl group, a phenylcarbonyl group, a cyclopropylmethylenecarbonyl group, a cyclobutylmethylenecarbonyl group, a cyclopentylmethylenecarbonyl group, a cyclohexylmethylenecarbonyl group, or 【Chemistry 24】 or R n is H; especially, 【Chemistry 25】 teeth, 【Chemistry 26】 It is.

9. Rn is C(O)R p where R p is selected from a C1-C15 alkyl group, wherein said C1-C15 alkyl group is optionally substituted with 1, 2 or 3 R, and R is selected from a C3-C12 cycloalkyl group, wherein said C3-C12 cycloalkyl group is optionally substituted with 1, 2 or 3 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C6-C10 aryl group substituted with a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C6-C10 aryl group substituted with a C1-C6 haloalkoxy group, and a C(O)C1-C6 alkyl group; Alternatively, Rn is OR p where R p is selected from a C1-C15 alkyl group, wherein the C1-C15 alkyl group is optionally substituted with 1, 2 or 3 R, and R is selected from a C1-C15 alkylamine group, wherein the C1-C15 alkylamine group is optionally selected from a halogen, a cyano group, a hydroxy group, a carboxy group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C6-C10 aryl group substituted with a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C6-C10 aryl group substituted with a C1-C6 haloalkoxy group, a C(O)C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C(O)OC1-C6 alkyl group and S(O) 2 or substituted with 1, 2 or 3 groups selected from the group consisting of C1-C6 alkyl groups; or, 【Chemical 27】 teeth, 【Chemistry 28】 wherein Rm is defined as in claim 1; or Alternatively, ring B is 【Chemical Formula 29】 The definition of the substituent in ring B is the same as R in claim 1, Alternatively, Rm is 【Chemistry 30】 Selected from Alternatively, Rn is 【Chemistry 31】 Selected from Alternatively, n is 0.

9. The compound according to any one of claims 1 to 8, or a stereoisomer or optical isomer, a pharma- ceutically acceptable salt, a prodrug or a solvate thereof.

10. A compound of formula I' or a stereoisomer or optical isomer, pharma- ceutically acceptable salt, prodrug or solvate thereof. 【Chemistry 32】 (where: X is O or CH 2 Selected from. X 1 is N or CR m1 Selected from. X 2 is N or CR m2 Selected from. X 3 is N or CR m3 Selected from. X 5 is N or CR' m3 Selected from. L is a bond, —O—, —S, or —NR m4 -, -C(O)- or -C(O)NR m4 -Selected from. Ring A and ring B are each independently selected from a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, and a 5-12 membered heteroaryl group, wherein the C3-C12 cycloalkyl group, the 3-12 membered heterocyclic group, the C6-C10 aryl group, and the 5-12 membered heteroaryl group are optionally substituted with 1-3 R. Each R m are independently H, D, a halogen atom, a cyano group, a hydroxyl group, a carboxyl group, -S(O) t R m5 , -C(O)R m5 , -C(O)OR m5 , -C(O)NR m6 R m7 , -S(O) t N.R. m6 R m7 , -C(O)NR m8 S (O) t N.R. m6 R m7 , -(CH 2 ) q S (O) t R m5 , -(CH 2 ) q C(O)R m5 , -(CH 2 ) q C(O)OR m5 , -(CH 2 ) q C(O)NR m6 R m7 , -(CH 2 ) q (CH 2 ) q S (O) t N.R. m6 R m7 , -C(O)NR m8 S (O) t N.R. m6 R m7 , -(CH 2 ) q R m9 , -C1-C6 alkyl group, -C1-C6 alkoxy group, -C1-C6 alkylamine group, C3-C12 cycloalkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted by 1-3 R, Alternatively, two R on adjacent ring atoms m together with the ring atoms adjacent thereto form a C3-C12 cycloalkyl group or a 3-12 membered heterocyclic group, wherein said C3-C12 cycloalkyl group or 3-12 membered heterocyclic group is optionally substituted with 1-3 R. R n is H, a C1-C15 alkyl group, a C2-C15 alkenyl group, a C2-C15 alkynyl group, C(O)R p where R p NH 2 , a C1-C15 alkyl group, a C1-C15 alkoxy group, a C1-C15 alkylamine group, a C2-C15 alkenyl group, a C2-C15 alkynyl group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group or a 5-12 membered heteroaryl group, wherein said C1-C15 alkyl group, C1-C15 alkoxy group, C1-C15 alkylamine group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group or a 5-12 membered heteroaryl group is optionally substituted by 1-3 R. R m1 , R m2 , R m3 and R' m3 are each independently H, a cyano group, a halogen, or C(O)NH 2 , carboxy group, S(O) 2 N.H. 2 , C(O)OC1-C6 alkyl group or S(O) 2 It is selected from C1-C6 alkyl groups. R m4 is selected from H or a C1-C6 alkyl group. R m5 is selected from a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group, wherein said C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group is optionally substituted by 1-3 R. R m6 , R m7 , R m8 and R m9 are each independently selected from H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylamine group, a C3-C12 cycloalkyl group, a 3-12 membered heterocyclic group, a C6-C10 aryl group, or a 5-12 membered heteroaryl group; or R m6 and R m7 form a 3-12 membered heterocyclic group together with the N atom adjacent thereto, wherein the C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally substituted with 1-3 R. (CH 2 ) q H in is optionally substituted with R. R is H, D, halogen, cyano group, hydroxy group, carboxy group, NH 2 , oxo group (=O), C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group, S(O) 2 C1-C6 alkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group, wherein said C1-C6 alkyl group, C1-C6 alkoxy group, C3-C12 cycloalkyl group, 3-12 membered heterocyclic group, C6-C10 aryl group or 5-12 membered heteroaryl group is optionally selected from halogen, cyano group, hydroxy group, carboxy group, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylamine group, C(O)OC1-C6 alkyl group and S(O) 2 It is substituted with 1 to 3 groups selected from the group consisting of C1-C6 alkyl groups. t is 0, 1 or 2. q is 1, 2, 3, 4, 5 or 6. n is 1, 2, 3, 4, 5 or 6.

11. The compound is as follows: 【Chemical 33】 【Chemical 34】 【Chemistry 35】 【Chemical Formula 36】 【Chemical 37】 【Chemical Formula 38】 【Chemical Formula 39】 【Chemistry 40】 【Chemistry 41】 【Chemistry 42】 【Chemistry 43】 2. The compound according to claim 1, wherein the compound is selected from the group consisting of:

12. A pharmaceutical composition comprising the compound according to any one of claims 1 to 11, or a stereoisomer or optical isomer thereof, a pharma- ceutically acceptable salt, prodrug or solvate thereof, and a pharma- ceutically acceptable carrier.

13. Use of a compound according to any one of claims 1 to 11 or a stereoisomer or optical isomer thereof, a pharma- ceutically acceptable salt, prodrug or solvate thereof, or a pharmaceutical composition according to claim 12, comprising For the manufacture of a drug for treating or preventing a disease associated with the activity or expression level of Drak2 kinase, or for the manufacture of a drug for suppressing the activity of Drak2 kinase, Preferably, the disease is cancer, an autoimmune disease or a metabolic disease, Here, the cancer is preferably malignant lymphoma, acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, diffuse large B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, basal cell carcinoma, breast cancer, brain cancer, adrenal cancer, kidney cancer, nephroblastoma, gastric cancer, gastrointestinal stromal tumor, pituitary adenoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon cancer, rectal cancer, small intestine cancer, duodenal cancer, retinoblastoma, choroidal melanoma, ampulla cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adenocarcinoma, nasal and paranasal cancer, small cell lung cancer, non-small cell lung cancer, astrocytoma, esophageal cancer, glioma, neuroblastoma, malignant soft tissue tumor, malignant bone tumor, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, penile cancer, oral cancer, lip cancer, pharyngeal cancer, epithelial ovarian cancer, ovarian germ cell cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, vaginal cancer, Paget's disease, tonsil cancer, anal cancer, rhabdomyosarcoma, Kaposi's sarcoma, sarcoma, tongue cancer, laryngeal cancer, pleural cancer, thymic cancer, or a combination thereof, wherein the non-small cell lung cancer is preferably lung adenocarcinoma or lung squamous cell carcinoma, The autoimmune disease is preferably selected from inflammatory colitis, Crohn's disease, Behcet's disease, multiple sclerosis, macular degeneration, arthritis, encephalitis, viral meningitis, or a combination thereof; The metabolic disease is preferably selected from diabetes, and the diabetes is preferably type 1 or type 2 diabetes, more preferably type 2 diabetes. The above-mentioned use.

Citation Information

Patent Citations

  • Biaryl pyridine deubiquitinating enzyme inhibitor as well as preparation method and application thereof

    CN107903208A

  • Biaryl-Substituted Thiazoles, Oxazoles, and Imidazoles as Sodium Channel Blockers

    JP2006523701A

  • New 2-thiophene carboxamide derivative

    JP2007262022A

  • selective kinase inhibitor

    JP2007517807A

  • PI3 kinase modulator and method of use

    JP2010535216A